Drug Design, Biological Activity, and Metabolic Consequences of Cytotoxic Platinum Compounds: Utilizing Fluorescent Tagging to Understand Drug Action and Metabolism by Benedetti, Brad
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2011
Drug Design, Biological Activity, and Metabolic
Consequences of Cytotoxic Platinum
Compounds: Utilizing Fluorescent Tagging to
Understand Drug Action and Metabolism
Brad Benedetti
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Chemistry Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/195
i 
 
 
Drug Design, Biological Activity, and Metabolic Consequences of 
Cytotoxic Platinum Compounds: Utilizing Fluorescent Tagging to 
Understand Drug Action and Metabolism 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University  
 
 
 
By  
Brad T. Benedetti 
B.S., Hampden-Sydney College, Hampden-Sydney, Virginia  
May, 2006  
 
 
 
Director: Dr. Nicholas P. Farrell  
Professor  
 
 
 
Department of Chemistry  
Virginia Commonwealth University  
Richmond, Virginia  
 
 
 
April, 2011 
  
ii 
 
Acknowledgements 
 
 This dissertation, as with all things in life, is the result of a combination of people 
and events that if alone could not have been possible. I first want to thank my advisor, 
Dr. Nicholas Farrell, for allowing me the opportunity to work on this project and to be 
involved with research of this caliber.  He has given me the opportunity to grow as a 
researcher and an individual, as well as the scientific freedom to follow my interests and 
ideas, no matter how far off based they may have been. And for this I will always be 
grateful. I would also like to thank Dr. Yun Qu, for her constant support over the years, 
and for being not just a colleague, but a true friend.  As I mentioned earlier, this work 
could not have been completed without the advice and direction of numerous post-docs 
and graduate students. I want to thank all present and past group members as well as 
my committee members for providing me with excellent guidance and mentorship over 
the last five years. 
 I would also like to thank, more that words can describe, the support, guidance, 
and love of my mother, Debra, and my brother, Cory.  They continued to believe in me, 
regardless of the situation or circumstances, or the extended amount of time obtaining a 
Ph.D. requires. I also want to thank my wife, Ana Paula, for her patience and enduring 
love during the last 3 years.  I could not have achieved the goals and dreams that I have 
achieved in my life without her love and support. 
 I would like to make a special acknowledgement and „thank you‟ to my father, 
William “Biff” Benedetti. I thank him for the love and guidance he has provided me 
throughout my entire life.  My passion and dedication to the field of cancer research 
unfortunately became a greater calling in 2005, when he was diagnosed with prostate 
cancer.  Sadly, he became a victim of this tragic disease on Nov. 15th 2011. The 
research of this work, as well as my passion for a treatment of this disease, is dedicated 
to him.  He will be greatly missed, but his memory lives on forever in our hearts and 
minds.  
iii 
 
Table of Contents 
 
List of Tables vii 
List of Figures viii 
List of Abbreviations xi  
Abstract xiii 
 
Chapter 1: Cancer and Platinum Based Chemotherapeutics 
 Cancer 1 
 Cisplatin and Platinum Analogs 1 
 Trans-Platinum Compounds 7 
 Polynuclear Platinum Compounds 9 
 Non-Covalent Polynuclear Platinum Compounds 9 
 Pharmacological Factors Affecting Platinum Based Treatments 14 
 Fluorescence Cellular Imaging of Platinum Compounds 17 
 Concluding Remarks and Project Overview 18 
 List of References 21 
 
Chapter 2: Modulation of protein-drug deactivation through carboxylate ligand 
modification in a series of cytotoxic trans-platinum planar amine compounds 
 Abstract 29 
 Introduction 30 
 Results and Discussion 32 
iv 
 
 Conclusion 48 
 Material and Methods 48 
 List of References 52 
 
Chapter 3: Pharmacokinetic Studies of Polynuclear Platinum Complexes with 
Plasma and Human Serum Albumin: Implications for Drug Design and Delivery 
 Abstract 55 
 Introduction 56 
 Results and Discussion 62 
 Conclusion 79 
 Material and Methods 79 
 List of References 83 
 
Chapter 4: Effects of non-covalent platinum drug-protein interactions on drug 
efficacy: Use of fluorescent conjugates as probes for drug metabolism 
 Abstract 87 
 Introduction 88 
 Results and Discussion 91 
 Conclusion 109 
 Material and Methods 110 
 List of References 117 
 
v 
 
Chapter 5: Design, Synthesis, and Anticancer Activity of Fluorescent-Based Dual 
Function trans-Platinum-NBD Complexes 
 Introduction 124 
 Results and Discussion 128 
 Conclusion 137 
 Material and Methods 138 
 List of References 143 
 
Chapter 6: Conclusion 147 
 
Appendix A: TriplatinNC, a Nucleolar-Targeting Agent, Disrupts rRNA 
Transcription Leading to G1 Arrest and p53-independent Apoptosis 
 Abstract 149 
 Introduction 150 
 Results and Discussion 154 
 Summary 173 
 Material and Methods 176 
 List of References 180 
 
Appendix B: Pre-association of polynuclear platinum anticancer agents on a 
protein, human serum albumin. Implications for drug design
 Abstract 185 
 Introduction 186 
vi 
 
 Results and Discussion 190 
 Conclusion 200 
 Experimental 201 
 List of References 205 
 
Vita   210 
 
 
 
 
  
vii 
 
List of Tables 
   Page 
Table 2.1 Effects of ligand substitution on methionine binding 39 
Table 2.2  Effects of serum binding on efficacy of trans-platinum  
  compounds in A2780 ovarian carcinoma cells 43 
Table 5.1 Binding affinities calculated by fluorometric titration 130 
Table 5.2 Cytotoxic activity of the Trans-NBD complexes and linkers 132 
Table 5.3 Cell accumulation and DNA binding for the Trans-NBD series 134 
Table A.1 Effect of cisplatin and TriplatinNC against the 2008 ovarian  
  tumor xenograft mouse model 175 
  
viii 
 
List of Figures 
   Page 
Figure 1.1 Chemical Structures of Clinical Platinum Chemotherapeutics 5  
Figure 1.2 DNA adducts formed after Cisplatin treatment 6  
Figure 1.3 Chemical structures of Trans-Platinum anticancer compounds 8 
Figure 1.4 Chemical Structures Selected Covalent and Non-Covalent  
  Polynuclear Platinum Compounds 11 
Figure 1.5 Long-Range DNA-Adducts formed by BBR3464 12 
Figure 1.6 Crystal Structure of TriplatinNC Interactions with DNA 13 
Figure 2.1 Structures of trans-platinum planar amine (TPA) carboxylate  
  compounds studied 35 
Figure 2.2 NMR Spectra of NAM with t-Pt(4-pic)NH3OFm 36 
Figure 2.3 NMR Spectra of NAM with t-Pt(4-pic)NH3OAc 37 
Figure 2.4 195Pt NMR Spectra of t-Pt(4-pic)NH3OAc reaction with NAM 38 
Figure 2.5 Effects of ligand substitution on HSA protein binding 41 
Figure 2.6 Influence of protein binding on platinum cellular uptake 45 
Figure 2.7 Influence of protein binding on DNA platination 47 
Figure 3.1 Chemical Structures of Cisplatin and Polynuclear  
  Platinum Compounds 60 
Figure 3.2 Chemical Structures of Selected Polynuclear Platinum Compounds 61 
Figure 3.3 Effects of mouse plasma binding on drug availability 63 
Figure 3.4 Effects of human plasma binding on drug availability 66 
Figure 3.5 Human Plasma Binding with BBR3610 and derivatives 67 
ix 
 
Figure 3.6 Human Plasma Binding with SET3007 and derivatives 68 
Figure 3.7 “Pre-Association” Effects and Significance of Electrostatic  
  Interactions on Human Serum Albumin Binding 71 
Figure 3.8 Crystal structure of human serum albumin 73 
Figure 3.9 Effects of Cysteine and Methionine peptide blocking  
  on BBR3464-HSA binding 74 
Figure 3.10 Charge density structure of human serum albumin 77 
Figure 3.11 Electrostatic Effects on HSA Global Structure 78 
Figure 4.1 Effect of BSO on platinum drug-induced cytotoxicity 93 
Figure 4.2 Effects of protein binding on free drug availability 95 
Figure 4.3 Influence of protein binding on platinum drug efficacy 97 
Figure 4.4 Influence of protein binding on platinum cellular uptake 100 
Figure 4.5 Influence of protein binding on DNA platination 102 
Figure 4.6 MTT cytotoxicity assay of fluorescent platinum derivatives 106 
Figure 4.7 Confocal laser scanning micrographs of A2780 cells 107 
Figure 4.8 Role of protein binding on the cellular localization and  
  distribution of cisplatin and TriplatinNC 108 
Figure 5.1 General Chemical Structure of Trans-NBD Compounds 127 
Figure 5.2 Confocal laser scanning micrographs of A2780 and HCT116  
  cells after incubation with Trans-NBD compounds 136 
Figure A.1 Structures of BBR3464, TriplatinNC and the Phosphate Clamp 153 
Figure A.2 Fluorescently-tagged TriplatinNC localizes to the nucleolus 155 
Figure A.3 MTT Assay of Fluorescently Tagged Compounds 156 
x 
 
Figure A.4 TriplatinNC competitively inhibits TBP-DNA interaction and  
  interferes with rRNA transcription 159 
Figure A.5 TBP Binding Assay with TriplatinNC and AH44 160 
Figure A.6 TriplatinNC induces G1 cell cycle arrest 161 
Figure A.7 Flow Cytometry; Cell cycle analysis of HCT116 cells treated  
  with Cisplatin 164 
Figure A.8 Flow Cytometry; Cell cycle analysis of HCT116, HCT116 p53-/-,  
  and HCT116 p21-/- cells 165 
Figure A.9 TriplatinNC causes rapid proliferative arrest and cell death 167 
Figure A.10 Clonogenic Survival Assay; Comparison of colonies formed  
  in HCT116 p53+/+ cells and HCT116 p53-/- cells 168 
Figure A.11 TriplatinNC induces activation of caspases independent of p53 171 
Figure A.12 Western Blot; Comparison of BID (p22) and the active  
  form, tBID (p15) proteins in HCT116 172 
Figure A.13 Antitumor activity of TriplatinNC against 2008 ovarian tumor  
  human xenograft model 174 
Figure B.1 Structures of pairs of trinuclear and dinuclear compouds studied  
  for pre-association effects on human serum albumin (HSA) 189 
Figure B.2 Changes in fluorescence of HSA treated with trinuclear  
  platinum compounds 191 
Figure B.3  CD spectra of HSA incubated with compounds 193 
Figure B.4 Nano-ESI-MS of rHSA incubated with platinum compounds 195 
Figure B.5 Changes in fluorescence of HSA treated with dinuclear  
xi 
 
  platinum compounds 197 
Figure B.6 ICP-OES analysis of Pt content in ultrafiltrate of BBR3464 and  
  Ia after incubation with HSA for selected time points 199 
  
xii 
 
List of Abbreviations 
5-FU 5-Fluorouracil 
A  Adenine (nucleobase)  
bp Base Pair  
C  Cytosine (nucleobase)  
Cisplatin/c-DDP cis-diamminedichloroplatinum(II) 
°C  Degrees Celsius  
Carboplatin cis-diammine-1,1-cyclobutane dicarboxylateplatinum(II) 
CD  Circular Dichroism 
D20 Deuterium Oxide 
Da  Dalton 
DDD  Dickerson-Drew Dodecamer  
DLT Dose limiting toxicity  
DNA Dideoxyribonucleic Acid  
Ds Double Stranded DNA  
ESI-MS Electrospray Ionization Mass Spectrometry 
G Guanine (nucleobase)  
GSH Glutathione 
HSA Human Serum Albumin  
HMG High Mobility Group 
IC50 Concentration to inhibit 50% of cell growth 
ICP-OES Inductively Coupled Plasma-Optical Emission Spectroscopy 
Isq Isoquinoline 
xiii 
 
ITC Isothermal Titration Calorimetry  
Ka Association Constant 
Kb Kilobase  
kDa Kilodalton  
M Molar  
m/z Mass-to-Charge Ratio  
mM Millimolar  
MRP Multi-drug resistance-associated protein 
MS Mass Spectrometry  
NAC N-Acetyl Cysteine 
NAM N-Acetyl Methionine 
NBD 4-Chloro-7-nitro-2,1,3-benzoxadiazole 
NMR Nuclear Magnetic Resonance  
Oxaliplatin [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II) 
PBS Phosphate Buffered Saline 
PDB ID Protein Database Identification Number 
PPC Polynuclear Platinum Compounds 
ppm Parts per Million 
Pt Platinum 
Ss Single Stranded DNA  
T Thymine (nucleobase)  
TPA Trans-Planar Amine 
Transplatin trans-diamminedichloroplatinum(II)  
xiv 
 
Abstract 
 
Drug Design, Biological Activity, and Metabolic Consequences of Cytotoxic 
Platinum Compounds: Utilizing Fluorescent Tagging to Understand Drug Action 
and Metabolism 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University  
 
By  
Brad T. Benedetti 
 
Director: Dr. Nicholas P. Farrell  
Professor  
Department of Chemistry, Virginia Commonwealth University  
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Platinum drugs are among the most commonly used chemotherapeutics for the 
treatment of testicular, head and neck, ovarian, small cell lung, and colorectal 
carcinomas.  Although the current set of platinum chemotherapeutics has proven 
somewhat successful, the overall success of platinum based drugs is limited due to 
acquired drug resistance and a limited range of tumor types that are treatable with the 
current regime. The development of novel cytotoxic platinum based compounds, both 
trans- and polynuclear, provides for the promising treatment of clinical platinum drug 
resistant tumors.  While the cytotoxic activity of platinum drugs provides for a hopeful 
outlook, the ultimate factors that affect the success of chemotherapeutics are the fine 
balance between cytotoxic activity and metabolic deactivation.  
In general, this work reports the drug design/drug action, and pharmacokinetic 
consequences of anticancer compounds aimed to fight mechanisms of cisplatin 
resistance. In the first project, we report the biological and biophysical studies aimed at 
xv 
 
understanding and improving upon the pharmacokinetic properties of 
chemotherapeutics; specifically, understanding their interactions with serum proteins. 
This work resulted in the discovery of using carboxylate ligands to modulate the 
reactivity of trans-platinum based compounds towards sulfur containing proteins with 
consequent effects on drug efficacy.  In addition, we report an in depth look into the 
biological consequences of non-covalent platinum drug-protein interactions on drug 
efficacy, and introduce the use of novel Platinum-NBD fluorescent conjugates as probes 
for drug metabolism. In the second project we report the design, synthesis, and 
biological consequences of fluorescent drug derivatives based on the NBD fluorophore, 
for use in understanding drug action and drug metabolism. As a result of this fluorescent 
drug labeling, TriplatinNC, a non-covalent platinum based chemotherapeutic, was found 
to specifically target nucleolar DNA/RNA, due to its high charge, and inhibit ribosomal 
RNA production in cancer cells.  The use of fluorescent derivatization also resulted in 
the development of a series of novel water-soluble trans-platinum complexes, with 
greater cytotoxicity than cisplatin. Therefore, these data resulted in the understanding 
of, and improvement upon the pharmacokinetic profile of platinum chemotherapeutics, 
as well as the development of novel fluorescent platinum conjugates with novel 
metabolic and cytotoxic profiles. 
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Chapter 1: Cancer and Platinum Based Chemotherapeutics 
 
1.1 Cancer 
Despite an enormous amount of research being committed to the treatment of cancer 
over the last few decades, cancer still remains a worldwide killer.  Deaths from cancer 
account for 23% of the total deaths in the United States, second only to heart disease.1 
While the number of deaths resulting from heart disease have been drastically reducing 
over the years, the total number of deaths from cancer remains constant.  Cancer is 
described as a class of diseases in which a group of cells display uncontrolled growth 
and invasion that intrudes upon and destroys adjacent tissues.  To date, there are 
multiple treatments available to fight the spread of cancer, including, surgery, 
chemotherapy, immunotherapy, and radiation therapy.2 Among the most commonly 
used chemotherapeutics for the prevention and treatment of cancer are Taxol, Cisplatin, 
Carboplatin, 5-FU and Doxorubicin.3 
 
1.2 Cisplatin and Platinum Analogs 
Cisplatin, c-DDP, cis-PtCl2(NH3)2 was first synthesized by Michel Peyrone in 1845
4, but 
remained relatively unnoticed until the early 1960‟s when Barnett Rosenberg, a 
professor of biophysics and chemistry at Michigan State University, began to investigate 
the effect of electrical currents on bacterial cell growth.5 (Figure 1.1) He discovered 
that after treatment with electrical current from "inert" platinum electrodes E. coli were 
produced that were 300 times their normal length. This treatment had successfully 
prevented cell division, but not other growth processes and ultimately led to the 
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elongation. Eventually, it was determined that the electric field applied to the E. Coli was 
not the cause of the elongation and that it was in fact the production of a platinum 
complex formed during reaction between the platinum electrodes and components of 
the media containing the bacteria. This platinum complex was eventually determined to 
be cis-PtCl2(NH3)2, cisplatin.  The serendipitous discovery of cisplatin changed the face 
of anti-tumour treatment of the 1970‟s.6  Cisplatin was eventually found to be highly 
effective against multiple tumor lines and entered into clinical trials in 1971 and was 
licensed solely to Bristol-Myers Squibb in 1977.7 
 The cytotoxicity of cisplatin is accepted to result mainly from the formation of 
bifunctional 1,2-intrastrand DNA crosslinks with purine bases,  resulting in the inhibition 
of DNA synthesis and replication.8 The most notable crosslinks seen are the 1-2-
intrastrand G-G adducts which form nearly 90% of the adducts.  Also possible is the 
formation of 1-2-interstrand adducts, but to a much lesser extent. (Figure 1.2) The DNA-
reactive platinum species are considered to be monoaquo and diaquo complexes – in 
general [Pt(amine)2(H2O)2]
2+ or [Pt(amine)2(Cl)(H2O)]
+ -   produced upon hydrolysis of 
the administered drugs, and the chemistry of these species has been well examined.9 
Following Cisplatin-DNA binding, the subsequent adduct is recognized by a high 
mobility group (HMG)-domain protein, which binds tightly to the Cisplatin-DNA 
complex.10-11 This adduct formation causes de-stacking of the nucleotide bases, 
resulting in the DNA helix becoming kinked. Therefore it is postulated that this 
interaction could potentially provide a “shielding” effect from typical DNA repair protein 
pathways.12 This inhibition of traditional DNA repair pathways results in the induction 
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cell signaling pathways, generally, p53, Bcl-2, caspases, and MAPK pathways, 
eventually leading to an apoptotic response.13 
 With the success of platinum based chemotherapy following the introduction of 
cisplatin in to the clinics in 1978, the development of subsequent platinum regimes has 
spiked tremendously.  Although this large amount of research has resulted in many 
promising compounds, only two subsequent platinum drugs, carboplatin and oxaliplatin, 
have been successfully approved for anti-cancer use by the FDA.7 (Figure 1.1) 
Carboplatin, invented by Rosenberg and his colleagues, was developed primarily to 
decrease the toxic side effects associated with cisplatin treatment, and is currently the 
only other platinum chemotherapeutic effective against a wide range of tumor types.14-15  
The addition of the bidentate cyclobutanedicarboxylate leaving group is more stable 
than the chloride groups of cisplatin, therefore slowing down the reactivity in the 
bloodstream and allowing more drug to reach the tumor intact.14  Oxaliplatin, the most 
recent platinum compound to be introduced to the clinics, was approved in across 
Europe in 1996 and in the United States in 2000 for use against advanced colorectal 
carcinoma.14,16  To date, Oxaliplatin is the only platinum chemotherapeutic to be 
approved for use against colorectal tumors.16 
 Following the development of cisplatin and initial studies on the general structure 
activity relationship of subsequent compounds, a set of rules was established to aid in 
the discovery of new platinum chemotherapeutics.17 These rules state that the 
compound(s) should have (1) two ammine groups in the cis geometry (2) two leaving 
groups also in the cis geometry (3) leaving groups which are only moderately easy to 
remove and (4) neutral charge.18 All current clinical platinum chemotherapeutics have 
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followed these rules.  Unfortunately the success of platinum based chemotherapeutics 
is limited due to eventual acquired drug resistance and a limited range of tumor types 
that are treatable with the current regime.  Therefore, the current research motivation is 
to find new platinum based drugs which exert a uniquely distinct mode of DNA binding, 
which could overcome clinical resistance to the currently used platinum drugs. 
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Figure 1.1  Chemical Structures of Clinical Platinum-Based Chemotherapeutics: 
Cisplatin (top left), Carboplatin (top right), and Oxaliplatin (bottom) 
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 Figure 1.2  DNA adducts formed after treatment of Cisplatin 
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1.3 Trans-Platinum Compounds 
One common feature among current clinical platinum therapeutics is the bis, cis 
orientation of the labile leaving groups.  The trans isomer of cisplatin, trans-[PtCl2(NH3)2] 
is much less toxic than the cis counterparts, presumably due to its inability to form 1,2-
intrastrand cross links between the N7 atoms of adjacent guanines in double strand 
DNA.19-20 Although transplatin itself is clinically inactive, substitution of one of the NH3 
groups with a planar heterocyclic ligand such as pyridine, thiazole, quinoline, 
isoquinoline, etc., yields a class of active transplanaramine platinum chemotherapeutics 
(TPA‟s).(Figure 1.3) These TPA compounds possess substantially enhanced 
cytotoxicity profiles as compared to the “parent” trans-[PtCl2(NH3)2], with IC50 values in 
the 1-10µM range across numerous tumor cell lines.21  Most interestingly, TPA 
compounds usually exhibit no cross resistance with cisplatin or oxaliplatin and thus 
demonstrate a unique cytotoxicity profile across the NCI tumor panel.22  The use of 
other carrier ligands such as iminoethers, heterocyclic aliphatic amines, and aliphatic 
amines, has also been used to produce a wide range of trans-platinum compounds with 
potential chemotherapeutic application.23-24   The use of carboxylates as leaving groups 
for TPA‟s has also been used, first introduced to address the low aqueous solubility of 
TPA‟s.25 These carboxylate derivatives have shown similar cytotoxicities to their parent 
chlorides.26-27 The use of carboxylate ligands also results in increased cellular 
accumulation even in cisplatin and oxaliplatin-resistant cell lines.26-27 In attempts to 
optimize drug design, previous studies in our group have shown that the use of formate 
as leaving group gives enhanced cytotoxicity in comparison to acetate.28  
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Figure 1.3  Chemical structures of selected Trans-Platinum based anticancer compounds.
29
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1.4 Polynuclear Platinum Compounds 
 Polynuclear platinum compounds represent a distinct class of anticancer drugs, 
whose structural and biological effects differ drastically from the classical mononuclear 
platinum family of compounds, (cisplatin, carboplatin, etc.).12,30 The first clinical 
compound resulting from this research, BBR3464, is a tri-nuclear, bi-functional DNA 
binding agent with an overall charge of 4+. (Figure 1.4)  BBR3464, the only non-
cisplatin-like molecule to enter human clinical trials, and has promising activity in 
cisplatin-resistant, cisplatin-sensitive and p53 mutant tumors.31-33  BBR3464 is also forty 
to eighty fold more potent on a molar basis than cisplatin.34  BBR3464 is capable of 
forming long range DNA adducts, including 1,4 and 1,6 inter-strand crosslinks. (Figure 
1.5)  The nature of these long-range adducts provides the basis for the enhanced 
cytotoxic nature of the compound and also for the ability BBR3464 to effectively treat 
cisplatin resistant tumors.35-36  
 
1.5 Non-Covalent Polynuclear Platinum Compounds 
 Most platinum chemotherapeutics bind to DNA in a covalent manner by 
formation of a Pt-DNA adduct.  Replacement of the chloride leaving groups of BBR3464 
with substitutionally „inert‟ ammine ligands or „dangling‟ ammines, H2N(CH2)6NH3
+, gives 
„non-covalent‟ polynuclear platinum compounds; most notably TriplatinNC. (Figure 1.4)  
TriplatinNC is a highly positively charged, (+8) non-covalent derivative of the phase II 
clinical platinum drug, BBR3464.37 The crystal and molecular structure of TriplatinNC 
associated with a double-stranded B-DNA dodecamer 5′-d(CGCGAATTCGCG)2  at 1.2 
Å resolution (PDB:2DYW), shows formation of phosphate clamps, involving two modes 
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of DNA binding: "backbone-tracking", by following along the phosphate backbone of one 
strand, or "groove-spanning", by crossing over the minor groove to interact with both 
strands.38 (Figure 1.6) The phosphate clamp motif is a discrete third mode of DNA 
binding, distinct from intercalation or minor groove binding. These interactions are 
mediated through hydrogen bonding, and are analogous to the "arginine fork”, an 
important motif for protein-DNA interactions, where positively charged guanidino groups 
of arginine, interact with negatively charged oxygens of DNA phosphate.39-41 TriplatinNC 
has significantly higher cellular accumulation than either BBR3464 or cisplatin, and in 
some cases equivalent or greater cytotoxicity than cisplatin.42-43  
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Figure 1.4  Chemical Structures Selected Covalent and Non-Covalent DNA Binding Platinum Drugs 
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Figure 1.5 Long-Range DNA-Adducts formed by BBR3464  
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Figure 1.6 Crystal Structure of TriplatinNC Interactions with DNA
44  
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1.6 Pharmacological Factors Affecting Platinum Based Treatments 
There are four main factors which control the pharmacokinetics of compounds in 
biological systems.  These factors include but are not limited to, absorption, distribution, 
metabolism, and elimination.  These four criteria greatly affect the bioavailability and 
kinetics of drug exposure towards the biological system of interest.  
Absorption refers to the ability of a drug, following administration, to effectively 
reach the systemic circulation; either by passing through intestinal cell membranes in 
the case of orally administered compounds or other natural membranes such as the 
blood brain barrier.45 Once in systemic circulation, the process of metabolism begins to 
decompose the compounds of interest into drug metabolites.  If the metabolites of the 
compound are „inert‟ after metabolism, a large portion of the pharmacological effect is 
thus diminished and the drug administered can no longer be distributed to the site of 
action. Metabolism can occur by reactions with liver redox enzymes such as 
cytochrome P450 and through interactions with proteins in the blood stream.46 
Prolonged elimination half-lives can result in reduced tolerability of the administered 
drug in patients, often warranting removal of compounds of interest from clinical trials.  
About 75% of drug candidates do not enter clinical trials due to pharmacokinetics 
problems in pre-clinical studies.  Also, about 40% of molecules that fail in clinical trials 
do so because of pharmacokinetics problems.46 
In addition to the pharmacokinetic properties that affect all administered drugs, 
the three major pharmacological factors affecting the success of any type of platinum-
based cancer therapy are cellular uptake, the frequency and the type of DNA adducts 
formed and metabolic deactivation. Metabolic deactivation is mediated through 
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interactions of the small molecules with biomolecules, specifically sulfur-containing 
amino acids in proteins, and these interactions may contribute to the toxic side effects 
associated with platinum based treatments.47-48 From a solely chemical standpoint, 
these metals, following aquation, would be expected to act as soft Lewis acids and to 
form stable complexes with S or N donors found in proteins.49 Thus, the rate of 
hydrolysis of the leaving ligand greatly affects the amount of protein binding.   
One of the most plausible extracellular non-DNA targets for platinum compounds 
is blood serum. Serum is the liquid portion of blood, approximately 55% of the total 
volume, excluding red and white blood cells, containing all plasma proteins at a 
concentration of 70 g/L.50 These proteins include fibrinogen, globulins, and human 
serum albumin (HSA).  Albumin, the most abundant plasma protein and the most likely 
candidate for drug metabolic interactions, is a 585 amino acid, 66 kDa, single chain 
protein involved in transportation of numerous drugs and ligands.51-52 HSA is largely α-
helical and contains 17 disulfide bridges and only one free cysteine, Cys-34.  This 
residue, along with Met-298 is speculated as the primary binding sites of cisplatin.53 It is 
mainly accepted, in the case of most Pt-compounds, that once coordinated to S or N 
donors in plasma proteins or other biomolecules, platinum compounds are effectively 
„deactivated‟ and eliminated from the body; thus never reaching their desired site of 
action.48 Severe nephrotoxicity has also been associated with interactions of platinum 
anti-tumor compounds with thiol groups of proteins.54 
Plasma proteins in the systemic circulation are not the only „deactivator‟ or 
scavenger of platinum chemotherapeutics.  Once removed from the systemic circulation 
and inside the cellular target there are a large number of molecules, in a high enough 
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concentration, to interact with the platinum moiety.55 Among these biomolecules of 
interest is the tri-peptide glutathione (GSH). Glutathione has been chosen due to its role 
as a determinant of cellular sensitivity to a wide variety of drugs and cytotoxic agents.  
The normal intracellular concentration of GSH ranges from 5 to 10 mM 56, therefore the 
binding of platinum-containing drugs to GSH is highly probable. Studies of interactions 
between GSH and c-DDP/transplatin showed the formation of a 1:1 Pt-GSH species in 
the case of the trans- isomer, and eventual liberation of the NH3 ligand to form a 1:2 Pt-
GSH species in the case of c-DDP.57-58 Also, clinical and preclinical studies of cellular 
systems with elevated levels of GSH have show to be more resistant, in varying 
degrees, to c-DDP.59 Studies with polynuclear platinum compounds have similarly 
shown the formation of Pt-GSH species in varying ratios, but ultimately, the interactions 
of these platinum compounds may be expected to follow that of cisplatin and its 
mononuclear analogues.60-61 Ultimately, therapeutic efficiency will be reflected as a 
balance between metabolic deactivating interactions and biological consequences of 
DNA toxicity. 
In an effort to improve the therapeutic efficiency, by minimizing interactions with 
plasma proteins, novel formulations of platinum compounds have been developed.62 
One pathway to minimize metabolic interactions can be through replacement of the 
most commonly used –Cl leaving group with other, more stable ligands.  Cell 
Therapeutics Inc. (CTI) is currently evaluating a derivative of the polynuclear platinum 
compound BBR3610 and has shown that replacement of the –Cl ligand with a 
carboxylate, such as butyrate or capronate, results in much lower plasma binding in 
vitro, while still retaining its cytotoxicity profile in vivo.63 This „carboxylate‟ strategy has 
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also been employed to improve the pharmacokinetic properties of mono-nuclear trans-
platinum compounds.25  In these trans-platinum compounds, carboxylate groups were 
added at first to simply enhance aqueous solubility, but have also been shown to 
decrease the rate of hydrolysis, therefore possibly allowing for decreased metabolic 
deactivation.  
 
1.8 Fluorescence Cellular Imaging of Platinum Compounds 
The use of molecular imaging techniques, such as fluorescence confocal 
microscopy, is an important tool in the understanding of platinum drug trafficking and 
intracellular distribution. Primarily, it is necessary to understand the ability of each 
compound to effectively penetrate the cell be delivered to the desired site of interest, in 
most cases, nuclear DNA.  Moreover, information regarding the subcellular 
compartments, transporters, and receptors with which these drugs localize can provide 
vital information explaining metabolic deactivation, resistance mechanisms, and toxicity.  
Hambley has summarized recent fluorescent approaches to monitoring platinum 
trafficking.64 Previous attempts at “tagging” platinum compounds have yielded cisplatin 
derivatives in which FITC and Alexa based fluorophores have been utilized. These 
derivatives tend to mimic the biological properties of the fluorescent “tag” rather than the 
platinum moiety itself.64 A number of platinum complexes incorporating fluorescent 
probes have been developed not just to monitor the localization of cisplatin, but rather 
as a class of potentially chemotherapeutic platinum drugs in their own right with the aim 
of combining the benefits of intercalating agents with those of platinum complexes.65-66 
The main objective to successfully create fluorescently labeled compounds that truly 
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mimic the biological properties of the parent compound is to minimize the size of the 
fluorescent probe and retain the original structure and solubility properties after 
conjugation.  
 
1.7 Concluding Remarks and Project Overview 
Despite an enormous amount of research being committed to the treatment of 
cancer over the last few decades, cancer still remains a worldwide killer.  Although the 
current set of platinum chemotherapeutics has proven somewhat successful, the overall 
success of platinum based chemotherapeutics is limited due to eventual acquired drug 
resistance and a limited range of tumor types that are treatable with the current regime.  
The development of novel cytotoxic platinum based compounds, trans- and polynuclear, 
provides for promising treatment of clinical “platin” drug resistant tumors.  While the 
cytotoxicity activity of many platinum drugs provides for a hopeful outlook, the ultimate 
factors affecting the success of chemotherapeutics are the fine balance between 
cytotoxic activity and metabolic deactivation.  By finding this balance,  it may be 
possible to defer many of the toxic side effects associated with chemotherapeutics, and 
thus provide for substantial increases in mean tolerated dosages, thus, facilitating the 
better development of platinum compounds for the treatment and prevention of cancer. 
The long term objective of this thesis was to evaluate, understand, and improve 
the pharmacokinetic profile of platinum chemotherapeutics through the use of standard 
biological and chemical protocols and through the development of novel fluorescent 
imaging assays.  Chapter 1 of this thesis presents an overview of platinum 
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chemotherapeutics and the role of metabolism in the overall activity of these 
compounds.   
Chapter 2 presents a series of cytotoxic trans-platinum compounds, in which we 
evaluate the ability of using carboxylate ligands to modulate the reactivity of the 
compounds towards sulfur containing proteins and consequently the biological effect on 
drug efficacy. The work in this chapter has been completed and is in submission to 
Dalton Transactions. 
In Chapter 3, the interactions of various polynuclear platinum complexes with 
mouse plasma, human plasma, and human serum albumin were studied. The 
implications for protein pre-association and plasma stability of polynuclear platinum 
compounds, both covalent and non-covalent are discussed. 
Chapter 4 builds on the biophysical studies observed in Chapter 3 and takes and 
in depth look into the biological consequences of non-covalent platinum drug-protein 
interactions on drug efficacy.  This chapter also introduces the use of novel Platinum-
NBD fluorescent conjugates as probes for drug metabolism. This work has been 
completed and is in submission to Molecular Pharmaceutics. 
 Chapter 5 reports the anticancer activity and primary insights into the mechanism 
of action of a series of novel water-soluble trans-platinum complexes that incorporate an 
amino ligand composed of an aliphatic carbon chain and a planar fluorophore 
intercalator, NBD.  This work has been completed and is in submission to JACS.   
Appendix 1 is a completed manuscript, in submission to PNAS, which discusses 
the biological consequences and mechanism of action of TriplatinNC, based on the 
fluorescent tagging of this compound with the NBD fluorophore.   Appendix 2 is also a 
20 
 
completed manuscript, published in Dalton Transactions, which focuses on the 
biophysical aspects of the pre-association of polynuclear platinum anticancer agents on 
a protein, human serum albumin and the implications for drug design.  
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Abstract 
Transplatinum planaramine (TPA) compounds which possess carboxylate 
ligands in the trans position have been shown to be potential antitumor drugs in a 
variety of cell types, including cisplatin and oxaliplatin resistance cell lines.1-3  In this 
work, we ask whether the nature and stability of the carboxylate ligand can be tuned in 
an attempt to manipulate the extent of serum protein binding; and consequently 
influence cytotoxicity, cellular drug accumulation and DNA adduct formation.  Monitoring 
the interactions of selected TPA‟s with N-Acetyl Methionine (NAM) by 1H and 195Pt NMR 
show large differences in rate of sulfur binding.  TPA containing acetate ligands show a 
much lower sulfur binding rate than those possessing formate leaving groups.  The 
same trend was seen after acetate and formate TPA compounds were incubated with 
human serum albumin and the reaction was monitored for 24hrs. To understand 
whether in vitro results could be translated in vivo, MTT cytotoxicity assays were 
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conducted for each compound, before and after incubation with whole serum.  Both the 
formate and acetate compounds, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2, 
showed minimal losses in cytotoxic efficacy and outperformed cisplatin after pre-
incubation with serum. The same trends were seen when monitoring the effects of 
protein binding on cellular uptake and DNA platination. The rate of protein binding/drug 
deactivation was shown to be directly related to the stability of the leaving group (OAc > 
OFm > Cl).  Thus, our results suggest that utilization of the „carboxylate strategy‟ 
substantially enhances the cellular efficacy of TPA compounds over cisplatin by 
allowing for an optimal balance between cytotoxic and metabolic efficiency. 
 
Introduction 
The platinum based chemotherapeutic, cisplatin, is among the most commonly 
used anticancer drug for the treatment of testicular, head and neck, ovarian, small cell 
lung, and colorectal carcinomas.4-5 The cytotoxicity of cisplatin results mainly from the 
formation of DNA crosslinks resulting in the inhibition of DNA synthesis and replication. 
6-7 However, the clinical effectiveness of cisplatin is limited due to inherent cellular 
resistance and dose-limiting side effects due to high levels of protein binding.8 One 
common feature among current clinical platinum therapeutics is the bis, cis orientation 
of the labile leaving groups.  The trans isomer of cisplatin, trans-[PtCl2(NH3)2] is much 
less toxic than the cis counterparts, presumably due to its inability to form 1,2-
intrastrand cross links between the N7 atoms of adjacent guanines in double strand 
DNA.9-10 
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Although transplatin itself is clinically inactive, substitution of one of the NH3 
groups with a planar heterocyclic ligand such as pyridine, thiazole, quinoline, 
isoquinoline, etc., yields a class of platinum chemotherapeutics, called 
transplanaramines (TPA‟s). These TPA compounds possess substantially enhanced 
cytotoxicity profiles as compared to the “parent” trans-[PtCl2(NH3)2], with IC50 values in 
the 1-10µM range across numerous tumor cell lines. Most interestingly, TPA 
compounds usually exhibit no cross resistance with cisplatin or oxaliplatin and thus 
demonstrate a unique cytotoxicity profile across the NCI tumor panel.2  Although these 
TPA compounds are relatively active, they are poorly water soluble and still posses high 
levels of protein binding due to the lability of the chloride leaving group. 
The most common modification to the TPA structures to address these issues is 
through replacing the chlorides with a more stable group of carboxylate ligands.  The 
use of carboxylates as leaving groups for TPA‟s was first introduced to address the low 
aqueous solubility of TPA‟s, but in preliminary studies showed that the „carboxylate‟ 
strategy could also been employed to improve the pharmacokinetic properties of mono-
nuclear trans-platinum compounds.11 These carboxylate derivatives have shown similar 
cytotoxicities to their parent chlorides.12-13 The use of carboxylate ligands also results in 
increased cellular accumulation even in cisplatin and oxaliplatin-resistant cell lines.12-13 
In attempts to optimize drug design, previous studies in our group have shown that the 
use of formate as leaving group gives enhanced cytotoxicity in comparison to acetate.1  
In order to evaluate the in vivo properties of these TPA compounds, it is first 
necessary to understand the three major factors affecting the clinical success of any 
type of platinum-based cancer therapy.  These factors include the rate of cellular 
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uptake, the frequency and the type of DNA adducts formed and metabolic deactivation. 
Although DNA is the proposed target for a majority of platinum chemotherapeutics, the 
first step in evaluating the clinical efficacy is to understand the metabolic interactions 
that occur following administration. One of the most plausible targets responsible for 
metabolic deactivation of platinum compounds is blood serum.  Serum is the liquid 
portion of blood, containing all serum proteins, at a concentration of 70 g/L.14  Among 
these proteins include globulin and serum albumin. Interactions of platinum anti-tumor 
compounds with sulfur containing amino acids in proteins have been shown to cause 
severe nephrotoxicity in patients and are responsible for a large portion of the toxic side 
effects associated with platinum based treatments.15 It is mainly accepted that once 
bound to plasma proteins, platinum compounds are „deactivated‟ and eliminated from 
the body. 
The development of oxaliplatin and carboplatin has shown the ability of using the 
carboxylate strategy to avoid these high levels of protein binding.16-17  Although this 
strategy has been used to improve the pharmacokinetic profile of cisplatin, and spurned 
the development of carboplatin and oxaliplatin, the use of the cis leaving group 
geometry still limits the treatment of these compounds in tumors which are currently 
“platin” resistant.  By extending the carboxylate strategy to TPA compounds it may be 
possible to avoid high levels of protein binding while concomitantly treating tumor types 
untreatable with current clinical platinum chemotherapeutics. 
 
Results and Discussion 
NMR Spectroscopy 
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It has previously been seen that modifying the leaving group ligand in a series of 
TPA compounds can greatly influence the rate of hydrolysis.11 To evaluate this change 
in hydrolysis rate and its effect on thiol binding, NMR binding studies of TPA‟s with N-
Acetyl-Methionine (NAM) were performed. (Figure 2.1)  The reaction of a series of a 
series of TPA‟s with acetate and formate leaving groups was monitored by 1H and 195Pt 
NMR spectroscopy. As seen in (Table 2.1), the reaction of t-Pt(4-pic)NH3(OFm)2 with 
NAM was followed by monitoring the H1 proton of 4-picoline and the CH proton of the 
formate leaving group.  Initial spectra at t = 0 show peaks at approximately δ = 8.25ppm 
for the H1 of 4-picoline. The spectrum acquired at t = 4hrs of a 1:2 t-Pt(4-
pic)NH3(OFm)2:NAM molar ratio reaction shows a shift of the H1 of 4-picoline from δ = 
8.25ppm to 8.67ppm. (Figure 2.2) After 4 hours, the peaks remained relatively 
unchanged, and 195Pt NMR was used to probe the resulting platinum coordination 
sphere.  The 195Pt NMR spectra showed only one peak at δ = -3340 ppm, consistent 
with a trans-bis thiol coordination to the platinum atom.18-19 Similar results were seen 
with the reaction of t-Pt(Isoquin)NH3(OFm)2 with NAM, indicating the dependence of 
protein binding on the formate leaving group and not the carrier ligand. (Table 2.1) The 
binding rates (t1/2) of each reaction were calculated and found to be 2.6 ± 0.2 hrs for t-
Pt(Isoquin)NH3(OFm)2 and 2.3 ± 0.1 hrs for t-Pt(4-pic)NH3(OFm)2. (Table 2.1) 
The same conditions were used to probe the binding rate of t-Pt(4-pic)NH3(OAc)2 
with NAM.  Initial spectra at t = 0 show peaks at approximately δ = 8.30ppm for the H1 
of 4-picoline. (Figure 2.3) Due to the slower rate of reactivity for the acetate ligand, the 
reaction was able to be monitored by both 1H and 195Pt NMR.  The resulting 195Pt NMR 
spectra showed only one peak at t = 0hrs, δ = -1445 ppm. After 4hrs, a second peak at 
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δ = -2860 ppm was observed. (Figure 2.4) This peak represents the displacement of 
one acetate group by NAM, with a coordination sphere of Pt[N2OS].  After 24hrs, the 
peak seen at δ = -2860 ppm disappeared and was replaced with a peak at δ = -3325 
ppm, consistent with a trans-bis thiol coordination of Pt[N2S2]. (Table 2.1) 
1H NMR 
spectra of the H1 of the 4-picoline revealed peaks at δ = 8.30, 8.55, and 8.70 ppm, 
indicating initial compound, mono-NAM and bis-NAM species respectively. (Figure 2.3) 
Similar results were seen with the reaction of t-Pt(Isoquin)NH3(OAc)2 with NAM. The 
binding rates (t1/2) of each reaction were calculated and found to be 10.1 ± 1.0 hrs for t-
Pt(4-pic)NH3(OAc)2 and 10.7 ± 0.8 hrs for t-Pt(Iso)NH3(OAc)2. (Table 2.1) 
By utilizing small molecules such as NAM as a model for drug-protein binding, it 
is possible to understand the contribution of the carboxylate ligand to metabolic 
deactivation and therefore predict the binding to larger serum proteins such as human 
serum albumin. These results show the ability of employing the carboxylate strategy as 
a way to manipulate high levels of drug-protein binding with TPA compounds.  These 
modifications have previously been shown to play a vital role in determining the 
cytotoxicity and cellular uptake of TPA compounds.20  Therefore, the general [PtN2O2] 
motif could allow researchers the capability of „„ﬁne-tuning” a balance between 
biological and metabolic activity of these compounds. 
  
35 
 
 
 
 
 
 
 
Figure 2.1 Structures of trans-platinum planar amine (TPA) carboxylate compounds studied. 
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Figure 2.2 NMR Spectra of t-Pt(4-pic)NH3OFm reaction with N-Acetyl Methionine  
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Figure 2.3 NMR Spectra of t-Pt(4-pic)NH3OAc reaction with N-Acetyl Methionine 
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Figure 2.4 
195
Pt NMR Spectra of t-Pt(4-pic)NH3OAc reaction with N-Acetyl Methionine after 0hrs (A) and 
4hrs (B) 
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(1) The reaction of t-Pt(4pic)NH3(OAc)2 and t-Pt(Isoquin)NH3(OAc)2 with methionine was sufficiently slow 
such that the mono-methionine product [Pt(N2OS)] was observed. δ 
195
Pt (ppm) = -2860 and δ 
195
Pt (ppm) 
= -2895 respectively. 
 
Table 2.1 Effects of ligand substitution on methionine binding:  Reaction of each TPA compound with N-
Acetly Methionine was monitored by 1H and 195Pt NMR spectroscopy. 
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Human Serum Albumin Binding 
To evaluate the effect of leaving group stability on protein binding, cisplatin, t-
Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 were incubated with human serum 
albumin and allowed to react for selected time points. The extent of drug-protein binding 
was analyzed by ICP-OES. Analysis of platinum content by ICP-OES shows a decrease 
in free drug availability over time for all three compounds. (Figure 2.5) This time 
dependent decrease in free drug availability represents a displacement of the platinum-
chloride or platinum-carboxylate bond and the formation of the covalent platinum-protein 
adduct.  As seen with the small molecule binding studies, the rate of protein binding is 
directly related to the stability/lability of the leaving group.  Within 30 minutes of 
incubation, approximately 25% of cisplatin was bound to serum albumin, while only 5% 
of both t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 were protein bound.  After 24hrs 
of protein exposure, approximately 85% of t-Pt(4-pic)NH3(OAc)2, and 50% of t-Pt(4-
pic)NH3(OFm)2 remain unbound to serum albumin, while only 20% of administered 
cisplatin remains in solution.  These studies show the ability to manipulate high levels of 
protein binding by modifying the stability of the carboxylate ligand. 
  
41 
 
 
 
 
Figure 2.5 Effects of ligand substitution on HSA protein binding: Binding of t-Pt(4pic)NH3(OAc)2 (white), t-
Pt(4pic)NH3(OFm)2 (grey), and Cisplatin (black) to human serum albumin over time.  Compounds were 
incubated with albumin (3:1) (drug:protein) and platinum content was observed by ICP-OES. 
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Effects of Protein Binding on Drug Cytotoxicity 
To further understand the translatability of utilizing the carboxylate strategy to 
improve the drug deactivation profile of TPA‟s, cytotoxicity assays were performed 
before and after incubation of TPA‟s with whole serum in A2780 ovarian carcinoma cell 
lines.  Cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 were incubated with 
whole serum for 0hr and 24hr and drug cytotoxicity was then examined.  Cisplatin 
shows a complete loss of cytotoxicity upon incubation with serum for 24hrs, with an 
observed IC50 increase of >30 fold. (Table 2.2)  Cellular treatment with t-Pt(4-
pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 after 24hr incubation with whole serum show 
only a 3-fold and 2-fold increase in IC50 value respectively. (Table 2.2) Although less 
cytotoxic in the control, once administered, a majority of the cytotoxic action of cisplatin 
is lost within a very short time due to interactions with serum proteins in the blood 
stream. In contrast, the cytotoxicity of t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 is 
retained after serum incubation. The rate of drug deactivation is directly related to the 
rate of hydrolysis, as the –OFm ligand is more labile than the –OAc ligand, which are 
both more stable than –Cl. Utilizing the bis-trans-geometry of the carboxylate groups 
provides little driving force for ligand substitution. This finding shows a class of drugs 
with significantly longer plasma half lives and decreased drug deactivation over current 
clinical platinum based chemotherapeutics. 
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Table 2.2  Effects of serum binding on efficacy of trans-platinum compounds in A2780 ovarian carcinoma 
cells.  Platinum compounds were incubated with whole serum for 24hrs and compared to control.  
Cellular grown inhibition was then measured by MTT after treatment.  
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Effects of Protein Binding on Cellular Accumulation 
Since the rate of cellular uptake and total accumulation correlates to the cytotoxic 
effect of platinum drugs, cellular accumulation of each platinum compound, before and 
after whole serum treatment, was examined. Treatment of A2780 cells with 10µM 
cisplatin produced an increase in cellular platinum levels reaching approximately 130 
attomole Pt/cell after 24hrs.  In contrast, cells treated with cisplatin, after a 24hr 
incubation period with whole serum prior to treatment, showed a drug accumulation of 
30 attomole Pt/cell. (Figure 2.6)  Cellular treatment with 10µM t-Pt(4-pic)NH3(OFm)2 
also shows a decrease in overall platinum accumulation after serum incubation, 310 
attomole Pt/cell in the control and 150 attomole Pt/cell after 24hr serum treatment.  
Serum pretreatment with 10µM t-Pt(4-pic)NH3(OAc)2 shows no significant decrease in 
overall platinum content as compared to the control; 90 attomole Pt/cell in both the 
control after 24hr serum incubation.  (Figure 2.6) While the serum pretreatment of t-
Pt(4-pic)NH3(OFm)2 results in a decrease in cellular uptake, the overall decrease in 
cellular uptake is only 2-fold, as compared to a 4-fold decrease for cisplatin. Once again 
the same trend is seen, where an increase in leaving group lability, Cl > OFm > OAc, 
results in increased protein binding and thus, a decrease in cellular uptake.  By 
minimizing interactions with serum proteins, TPA compounds have the ability to 
maintain high levels of cellular uptake and thus a greater level of cytoxocity over 
metabolic deactivation.   
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Figure 2.6 Influence of protein binding on platinum cellular uptake in A2780 ovarian carcinoma cells. 
A2780 Cells were treated with 10µM cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 before and 
after serum pretreatment for 24hrs. After 24hr cellular treatment of each compound, cells were removed 
from the plate and analysis of platinum content was performed on a Varian ICP-MS. Values are the 
average (+/- S.E.M.) of three independent experiments. 
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Effects of Protein Binding on DNA Platination 
 The cytotoxicity of platinum chemotherapeutics is mainly accepted to be 
modulated by the frequency and type of platinum-DNA adducts formed during drug 
treatment.  Upon treatment, TPA compounds promote DNA strand breaks, interstrand 
cross-links and ultimately trigger the apoptosis cascade, resulting in programmed cell 
death.1  To examine the role of protein binding on the levels of DNA platination, A2780 
cells were treated for 24hrs with 10µM cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-
pic)NH3(OAc)2 before and after serum pretreatment.  DNA platination levels after 24 
hours of continuous cisplatin treatment reached approximately 675 nmole Pt/g DNA, 
while platinum levels of cisplatin pretreated with whole serum remained less than 40 
nmole Pt/g DNA. (Figure 2.7) The same trend in DNA adduct formation, albeit at a 
lesser extent, was seen with t-Pt(4-pic)NH3(OFm)2, with platinum levels reaching 245 
nmole Pt/g DNA in the control and 70 nmole Pt/g DNA after pretreatment with serum. 
(Figure 2.7) In contrast, DNA platination levels after 24 hours of continuous t-Pt(4-
pic)NH3(OAc)2 treatment remained constant in both the control and after 24hrs of serum 
pretreatment, with levels reaching approximately 70 nmole Pt/g DNA.  While initial 
platination levels of both t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 are lower than 
seen with cisplatin, after 24hrs of serum pretreatment, both t-Pt(4-pic)NH3(OFm)2 and t-
Pt(4-pic)NH3(OAc)2 outperform cisplatin and retain a large portion of their cytotoxic 
profile. 
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Figure 2.7 Influence of protein binding on DNA platination in A2780 ovarian carcinoma cells. A2780 Cells 
were treated with 10µM cisplatin, t-Pt(4-pic)NH3(OFm)2 and t-Pt(4-pic)NH3(OAc)2 before and after serum 
pretreatment for 24hrs. After 24hrs of drug exposure, cells were removed from the plate and washed with 
PBS. Cellular DNA was then extracted and analysis of platinum content was performed on a Varian ICP-
MS. Values are the average (+/- S.E.M.) of three independent experiments. 
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Conclusion 
The development of novel cytotoxic transplatin compounds provides for 
promising treatment of clinical “platin” drug resistant tumors.  By understanding the 
balance between cytotoxic activity and metabolic deactivation it is possible to defer 
many of the toxic side effects associated with chemotherapeutics, and thus provide for 
substantial increases in mean tolerated dosages. Here, we evaluate the ability of using 
carboxylate ligands to modulate the reactivity of TPA compounds towards sulfur 
containing proteins.  We have found that by increasing the stability of the leaving group 
leads to decreased protein binding and thus allows for increase cytotoxic activity after 
pre-incubation with serum proteins.  The acetate ligand was shown to be the most 
stable, followed by the formate and chloride, respectively.  Although the stability of the 
acetate group ultimately provides for the least reactivity towards proteins, this enhanced 
stability also provides for decreases in DNA binding and therefore a slightly less potent 
IC50 is seen when compared with the formate derivative.  These results show the 
importance of understand the balance between cytotoxicity and metabolic deactivation.  
The use of carboxylates in this process ultimately provides the means to “fine-tune” the 
reactivity of trans-platinum compounds and therefore provides a balance between the 
cytotoxic and pharmacokinetic profiles. 
 
Methods 
Materials 
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All compounds were synthesized according to methods reported previously. 1,11,20 
Albumin from human, 99% and N-Acetyl Methionine was purchased from Sigma.  Fetal 
Bovine Serum (FBS) was purchased from Atlanta Biologicals. 
 
NMR Spectroscopy 
A stock solution of both deuterated (DPBS) and normal (PBS) phosphate-
buffered saline ([phosphate] = 150 mM, pH 7.35 at 37° C, [NaCl] = 120 mM, [KCl] = 2.7 
mM) was prepared for all reaction solutions to mimic physiological conditions. Platinum 
compounds were incubated with N-Acetyl-Methionine at a reaction ratio of 1:2 (Platinum 
Complex : N-Acetyl-Methionine) at 37oC. 1H NMR and 195Pt NMR spectra were recorded 
at various time points up to 24hrs. 1H NMR and 195Pt NMR spectra were recorded on a 
Varian Mercury series 300 MHz NMR spectrometer using a 5 mm probe for 1H and a 10 
mm broad-band probe for 195Pt. 1H spectra were referenced to sodium 3-(trimethylsilyl)-
propionate (TSP) at δ = 0 ppm, and 195Pt spectra were referenced to Na2[PtCl6]. The 
scanning frequency for 195Pt nuclei was set at 64.32 MHz. 
 
Human Serum Albumin Binding 
For HSA binding, 50μL of 1.8mM solutions of each complex were prepared in 
PBS, pH 7.4 and added to 50μL of 0.6 mM HSA such that the final drug concentration 
was 0.9 mM. (3:1; Drug:HSA)  The reactions were incubated at 37 °C for 0, 0.5, 2, 6, 
and 24 hours.  Unreacted drug was removed by centrifugation through a Millipore 
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Microcon YM-10 (10,000 kDa) membrane filter at 14,000xg for 30 min.  The centrifuge 
cup was upturned in a second eppendorf and centrifuged at 1000xg for 3 min to isolate 
the protein-bound drug. The digestion procedure followed published methods.21  
Analysis of platinum content for both the protein-bound and unreacted samples was 
performed on a Varian ICP-OES. 
 
Cellular Growth Inhibition 
The MTT assay was used to determine growth inhibition potency of platinum 
drugs before and after incubation with FBS.22  A2780 cells were seeded in 96-well 
plates at 6,500 cells/well in 200μL RPMI 1640 media supplemented with 10% FBS and 
1% Penicillin:Streptomycin and allowed to attach overnight. Media was removed and 
200µL of each compound was added after serial dilution in quadruplicate wells and 
exposed to cells for 72h.  For time dependent media incubation studies 500µM of each 
Pt compound was incubated in FBS (1:10 v/v) for 24hrs before cellular treatment.  
Samples were diluted to treatment concentrations with fresh media and exposed to cells 
for 72hrs.  After 72hrs, drug solution was removed and plates were washed with PBS. 
100µL of 5mg/mL MTT solution was added and solution was incubated with cells for 3h 
at 37oC. After incubation, MTT solution was removed and 100µL of DMSO was added.  
Quantification of cell growth in treated and control wells was then assessed by 
measurement of absorbance at 562nm. IC50 values were determined graphically. 
 
Cellular Uptake of Drug Complexes 
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A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to 
attach overnight. Cells were then treated with 10µM of each drug for 24hrs before and 
after serum incubation. After 24hrs, drug solution was removed and plates were washed 
3x with PBS.  Cells were then removed from the dish with trypsin and centrifuged for 
5min at 1000xg. Media was removed, cell pellet was washed three times with PBS, cells 
were counted and resuspended in 250μL of ddH20.  Samples were digested following 
published methods.21  Analysis of Pt content was performed on a Varian ICP-MS. 
Standards and blank were prepared similarly. 
 
Quantification of DNA-Drug Adducts 
A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to 
attach overnight. Cells were then treated with 10µM of each drug for 24hrs before and 
after serum incubation. After 24hrs, drug solution was removed and plates were washed 
3x with PBS.  Cells were then removed from the dish with trypsin and centrifuged for 
5min at 1000xg. Media was removed, cell pellet was washed three times with PBS and 
suspended in 250μL of ddH20.  DNA was extracted using a DNeasy blood and tissue kit 
(Qiagen) according to the manufacturer‟s protocol.  Extent of DNA platination was 
measured on a Varian ICP-MS. 
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Abstract 
The interactions of various polynuclear platinum complexes with mouse plasma, 
human plasma, and human serum albumin were studied. Some of the compounds 
examined were the “non-covalent” analogs of the trinuclear BBR3464 as well as the 
dinuclear compounds differing in only the presence or absence of a central –NH2–
+ 
(SET3007 and analogs). The rate and extent of platinum-protein adduct formation was 
monitored by ICP-OES and evidence for pre-association, presumably through 
electrostatic and hydrogen-bonding, was obtained by fluorescence spectroscopy and 
through the use of methionine and cysteine blocked human serum albumin. In the case 
of those compounds containing Pt-Cl bonds, further reaction took place presumably 
through displacement by sulfur nucleophiles, while the non-covalent derivatives showed 
an initial formation of a platinum-protein complex, but no change in complex formation 
over time.  The implications for protein pre-association and plasma stability of 
polynuclear platinum compounds, both covalent and non-covalent are discussed. 
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Introduction 
There are four main factors which control the pharmacokinetics of compounds in 
biological systems.  These factors include but are not limited to, absorption, distribution, 
metabolism, and elimination.  These four criteria greatly affect the bioavailability and 
kinetics of drug exposure towards the biological system of interest. Absorption refers to 
the ability of a drug, following administration, to effectively reach the systemic 
circulation; either by passing through intestinal cell membranes in the case of orally 
administered compounds or other natural membranes such as the blood brain barrier.1 
Once in systemic circulation, the process of metabolism begins to decompose the 
compounds of interest into drug metabolites.  If the metabolites of the compound are 
„inert‟ after metabolism, a large portion of the pharmacological effect is thus diminished 
and the drug administered can no longer be distributed to the site of action. Metabolism 
can occur by reactions with liver redox enzymes such as cytochrome P450 and through 
interactions with proteins in the blood stream.2 Prolonged elimination half-lives can 
result in reduced tolerability of the administered drug in patients, often warranting 
removal of compounds of interest from clinical trials.  About ¾ of drug candidates do not 
enter clinical trials due to pharmacokinetics problems in animals.  Also, about 40% of 
molecules that fail in clinical trials do so because of pharmacokinetics problems.2 
Therefore, these points ultimately control the outcome of drugs introduced into the 
clinics. 
One drug which encountered pharmacokinetic problems via metabolic 
interactions in the clinical setting is the anti-tumor agent BBR3464 (Figure 3.1). 
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BBR3464, a novel tri-platinum compound, has demonstrated promising activity in 
cisplatin-resistant, cisplatin-sensitive and p53 mutant tumors. BBR3464 is also forty to 
eighty fold more potent on a molar dose basis than its predecessor and most commonly 
used platinum anticancer agent cisplatin, c-DDP (Figure 3.1). Although providing 
promising pre-clinical and Phase I clinical studies, in Phase II studies BBR3464 showed 
higher plasma protein binding in human than mice and a more rapid degradation of 
BBR3464 into inactive metabolites.  These pharmacokinetic factors, along with reduced 
activity in gastric and lung cell carcinomas, have discouraged the use of BBR3464 in 
the clinical setting.3-7 Therefore, there is a need for the development of novel platinum 
compounds to circumvent these factors. 
Synthesis, characterization, and biological evaluation of a large variety of novel 
polynuclear platinum anti-cancer drug candidates have taken place since the 
introduction of BBR3464 into the clinics in the late „90s.8-12  Polynuclear platinum 
compounds which employ polyamine linkers of variable chain length represent a new 
class of anti-tumor agents showing activity profiles different from c-DDP.13-14  These 
drugs use a „covalent‟ mode of DNA binding, similar to c-DDP by displacement of the 
Pt-Cl bond and formation of a coordinate Pt-DNA adduct. Due to the ease of 
aquatablility of the –Cl leaving group, subsequent Pt-protein bond formation is still a 
prevalent problem, thus diminishing the overall effect of platinum chemotherapeutic 
compounds. Replacement of the -Cl leaving groups with substitutionally „inert‟ NH3 
ligands introduces an entirely novel class of „non-covalent‟ polynuclear platinum 
compounds. (Figure 3.2 (AH44 and TriplatinNC)) The presence of hydrogen-bonding 
and electrostatic interactions contributes to the unique profile of this group of drugs.  
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The presence of a charge in the linker, either as the central tetra-amine unit of a 
trinuclear compound or through a polyamine linker in a dinuclear species, greatly 
enhances anti-tumor activity for this „non-covalent‟ class.15 
Although DNA is the core target for the vast majority of platinum anti-cancer 
compounds, the first step in probing the clinical effectiveness of these drugs is to fully 
understand the metabolic interactions that may occur with these compounds while 
traveling through the systemic circulation towards their desired site of action.  From a 
solely chemical standpoint, these metals, following aquation, would be expected to act 
as soft Lewis acids and to form stable complexes with S or N donors found in proteins.16 
Thus, the rate of hydrolysis of the leaving ligand greatly affects the amount of protein 
binding.  Albumin, the most abundant plasma protein and the most likely candidate for 
drug metabolic interactions, is a 585 amino acid, 66 kDa, single chain protein involved 
in transportation of numerous drugs and ligands.17-18 HSA is largely α-helical and 
contains 17 disulfide bridges and only one free cysteine, Cys34.  This residue, along 
with Met298 is speculated as the primary binding sites of c-DDP.19 It is mainly accepted, 
in the case of most Pt-compounds, that once coordinated to S or N donors in plasma 
proteins or other biomolecules, platinum compounds are effectively „deactivated‟ and 
eliminated from the body; thus never reaching their desired site of action.20 Severe 
nephrotoxicity has also been associated with interactions of platinum anti-tumor 
compounds with thiol groups of proteins.21-22 
In an effort to improve the therapeutic efficiency, by minimizing interactions with 
plasma proteins, novel formulations of platinum compounds have been developed [46]. 
One pathway to minimize metabolic interactions can be through replacement of the 
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most commonly used –Cl leaving group with other, more stable ligands.  Cell 
Therapeutics Inc. (CTI) is currently evaluating a derivative of the polynuclear platinum 
compound BBR3610 and has shown that replacement of the –Cl ligand with a 
carboxylate, such as butyrate or capronate, results in much lower plasma binding in 
vitro, while still retaining its cytotoxicity profile in vivo.23 In this sense, it is possible to 
minimize the extent of protein binding by modifying the labile leaving group attached to 
the platinum moiety. 
A study of the interactions of BBR3464 and other polynuclear platinum drugs 
(Figure 3.1, 3.2) with plasma proteins such as albumin has not been as thoroughly 
investigated as have the interactions with glutathione and other biomolecules. As one of 
the major contributors to Pt-S binding, albumin, and more specifically its interactions 
with platinum compounds must be investigated and the pharmacokinetics of these 
potential drug candidates‟ interactions understood. An understanding of the effects of 
ligand substitution rates and geometry contribution can also provide new tools to aid in 
drug discovery and development. The long term goal is therefore to evaluate, 
understand, and improve the pharmacokinetic profile of platinum chemotherapeutics in 
an attempt to prevent drug deactivation and diminish toxic side effects thus, facilitating 
the better development of platinum compounds for the treatment and prevention of 
cancer. 
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Figure 3.1 Chemical Structures of Cisplatin and Polynuclear Platinum Compounds. 
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Figure 3.2 Chemical Structures of Selected Polynuclear Platinum Compounds.  
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Results and Discussion 
Mouse Plasma Binding with Selected -Cl Polynuclear Platinum Compounds 
Plasma is the liquid portion of blood, approximately 55% of the total volume, not 
including red or white blood cells, in which all plasma proteins are contained.20  Among 
these proteins include fibrinogen, globulins, and human serum albumin (HSA).  Due to 
the discrepancy found between levels of protein binding in mouse plasma and human 
plasma with BBR3464, it was necessary to first evaluate the binding of selected 
polynuclear platinum compounds with mouse plasma. Cisplatin, BBR3464 and 
BBR3610 were incubated with rehydrated mouse plasma for 0-24 hrs and the extent of 
platinum-protein binding was analyzed by ICP-OES. (Figure 3.3) Binding of Cisplatin, 
BBR3464 and BBR3610 to plasma proteins was found to increase with time, which can 
be expected as Pt-Cl bond dissociation occurs and Pt-protein bond formation increases.  
Percentages noted on all data represent the percentage of “free-drug” available, drug 
that has not been deactivated due to protein binding. It is worth observation that c-DDP 
shows a much higher free drug percentage at all time points than do BBR3464 and 
BBR3610.  This interaction could be a result of the high charge associated with both 
BBR3610 and BBR3464.  In the early time points, there is an immediate interaction with 
the protein, much faster than can be accounted for with only Pt-Cl bond displacement.  
This initial decrease in free drug availability is a combination of both electrostatic charge 
interactions and covalent Pt-protein bond formation.  Due to this high charge, BR3464 
shows much higher plasma binding over time than cisplatin. 
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Figure 3.3 Effects of mouse plasma binding on drug availability.  Cisplatin, BBR3464 and BBR3610 were 
incubated with mouse plasma for selected time points and platinum content for protein bound and free 
drug was analyzed by ICP-OES. 
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Human Plasma Binding with Selected Polynuclear Platinum Compounds (PPC‟s) 
Further evaluation of a larger group of PPC‟s was continued by investigating the 
binding between PPC‟s and human plasma. Compounds included in this study provided 
for the analysis of differences in charge and leaving group lability on Pt-protein binding. 
Cisplatin and BBR3464 were first analyzed to confirm the discrepancy found between 
binding in mouse plasma and human plasma with BBR3464 in the clinics.  At the 0.5hr 
time point, in mouse plasma and human plasma, the percentage of unbound c-DDP 
was approximately 70%-80%, while the percentage of unbound BBR3464 was 35% in 
mouse plasma but only 15% in human plasma.  Similar observations can be made at 
subsequent time points. (Figure 3.4) BBR3610 shows a slower rate of protein binding as 
compared to BBR3464, but after 24hrs the overall amount of free drug available is still 
less than 10%. Figure 3.5 shows the effects of addition of -Boc and -Dach groups, used 
to decrease overall charge and mimic oxaliplatin structure respectively, on the rate of 
drug-protein binding.  By adding the -Dach chelate in place of the bis ammonia carrier 
ligands, the position of the chloride is thus shifted to the –cis position.  Although in the –
cis position, the amount of protein binding is ultimately unchanged as compared to the 
parent BBR3610 complex.  This trend is also seen with the addition of –Boc alone, and 
in combination with –Dach (BBR3610-Dach-Boc) Both of these drug derivatives show 
similar levels of protein binding as BBR3610.  Also shown in Figure 3.5 is the effect of 
ligand substitution of protein binding.  Due to decreased hydrolysis rates caused by 
substitution of -Cl for -NO2, protein binding in BBR3610-NO2 is significantly lower than in 
the case of BBR3610 at similar time points. Free drug percentage in the case of 
BBR3610-NO2, approximately 30% after 24hrs, shows a significant improvement over 
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BBR3464, BBR3610 and also cisplatin. Although substitution of –Cl for –NO2 has 
proven to be not clinically relevant, the concept of ligand substitution based on 
decreasing hydrolysis rates has shown that a decrease in metabolic activity is 
accessible through ligand substitution.  These results were also observed with the 
SET3007 series. (Figure 3.6) Therefore the driving force behind the extent and rate of 
drug protein interactions are a direct result of the stability of the leaving group.  This 
result gives support to further investigate the effect of leaving group ligands on the 
binding on PPC‟s to plasma proteins. 
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Figure 3.4 Effects of human plasma binding on drug availability.  Cisplatin, BBR3464 and BBR3610 were 
incubated with human plasma for selected time points and platinum content for protein bound and free 
drug was analyzed by ICP-OES. 
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Figure 3.5 Human Plasma Binding with BBR3610 and derivatives. Compounds were incubated with 
human plasma for selected time points and platinum content for protein bound and free drug was 
analyzed by ICP-OES. 
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Figure 3.6 Human Plasma Binding with SET3007 and derivatives. Compounds were incubated with 
human plasma for selected time points and platinum content for protein bound and free drug was 
analyzed by ICP-OES. 
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Significance of Electrostatic Interactions on Human Serum Albumin Binding 
The role of pre-association in dictating the final products of reactions of PPCs 
with biomolecules has been assisted greatly in the trinuclear case by the synthesis and 
evaluation of “non-covalent” analogs where the Pt–Cl bonds are displaced by a 
substitution-inert NH3 or a “dangling” amine H2N(CH2)6NH3
+. In order to better 
investigate these types of interactions, human serum albumin (HSA) was selected as 
the protein of interest.  Human serum albumin is a versatile transport protein and 
receptor for a variety of ligands and drugs. The primary function of HSA is the transport 
of fatty acids but since it carries a negative 17 charge, it is also responsible for shuttling 
a wide variety of metal ions, steroids, and a variety of pharmaceuticals.24-25 HSA 
constitutes roughly 60% of the mass of plasma proteins with a concentration of ∼40 
mg/mL. It is highly likely therefore that HSA binding could contribute to these metabolic 
deactivation reactions, as suggested also for some similar dinuclear complexes.10  To 
evaluate and quantitate the binding of PPC‟s to HSA, BBR3464, BBR3610, Cisplatin, 
AH44 and TriplatinNC were incubated and the ultrafilterable protein unbound fraction 
was quantified for selected time points.(Figure 3.7) Analysis by ICP-OES shows a 
decrease in Pt content immediately upon mixing, t = 0, for all compounds, excluding 
cisplatin. This initial decrease in Pt content represents the non-covalent, “pre-
association” of the Pt complex with protein. The Pt content corresponding to compounds 
containing a Pt-Cl bond decreases with time, representing a displacement of the Pt–Cl 
bond and a formation of the coordinate/covalently bound Pt–protein species (where 
covalent is used to indicate Pt–amino acid residue formation independent of strict 
contributions of covalent or coordinate bonding). In contrast, ICP-OES analysis of AH44 
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and TriplatinNC shows a constant Pt concentration from t = 0 through t = 24 h. Due to 
the presence of the substitution-inert –NH3 group, the initial pre-association is not 
followed by a covalent Pt–protein interaction.  The results for AH44 and TriplatinNC 
suggest that these non-covalent compounds may “by-pass” the deactivation associated 
with Pt–S bond formation.  
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Figure 3.7 “Pre-Association” Effects and Significance of Electrostatic Interactions on Human Serum 
Albumin Binding: Compounds were incubated with human serum albumin for selected time points and 
platinum content for protein bound and free drug was analyzed by ICP-OES. 
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HSA Protein Modification and Binding Site Evaluation 
Previous studies on the identification of the cisplatin binding site on HSA have 
been shown to be a combination of both free sulfur containing amino acids, Cys-34 and 
Met-298.19,26-27 Although HSA contains 35 cysteine amino acids, 34 are involved in 
disulfide bridges and only one free cysteine remains.  As seen in the Figure 3.8, both 
Met-298 and Cys-34 are located on the solvent accessible surface of HSA and are valid 
candidates for the binding of platinum chemotherapeutics.  In the case of BBR3464, the 
addition of a high charge component could cause the drug to specifically or 
preferentially bind to one amino acid or another.  Therefore, in this regard, we examined 
the role of amino acid blocking and its effect on the binding of BBR3464 to native and 
modified HSA.  BBR3464 was incubated with Cysteine and Methionine blocked HSA 
and the reaction was monitored by ICP-OES.(Figure 3.9) Cysteine blocked HSA shows 
equal amounts of free drug after each time point as the native HSA protein.  This 
suggests that Cysteine binding does not play a major role in the binding of BBR3464 to 
HSA.  On the other hand, after the blocking of Methionine residues, Pt-protein bond 
formation is effectively eliminated.  This suggests that Met residues on HSA are the 
major contributor of Pt deactivation for BBR3464.  Also, it is important to note that even 
after blocking methionine residues on HSA, approximately 20% of administered 
BBR3464 interacts with the protein. This effect is the pre-association of the positively 
charged drug, presumably, with negative regions of HSA. 
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Figure 3.8 Crystal structure of human serum albumin with Met-298 and Cys-34 highlighted in red.  Figure 
adapted from PDB ID: 1BM0 
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Figure 3.9 Effects of cysteine and methionine peptide blocking on BBR3464-HSA binding. Compounds 
were incubated with human serum albumin for selected time points and platinum content for protein 
bound and free drug was analyzed by ICP-OES.  
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Effects of Charge on HSA Global Conformation 
As seen in Figure 3.10, the charge density map of HSA shows multiple regions of 
negative charge, shown in red, where the cationic platinum compounds could first 
interact and subsequently bind to S-containing amino acids.  To understand and 
examine these changes, fluorescence spectroscopy was utilized.  The fluorescence 
from excitation of HSA at 298nm reflects changes in the microenvironment of the 
tryptophan 214 residue, serving as a tool to obtain information about conformational 
changes of the protein.28 A decrease in fluorescence of the lone tryptophan of HSA is 
interpreted as a conformational change making the amino acid more accessible to water 
quenching. The covalent binding and cationic BBR3464, was used to investigate these 
interactions. Upon incubation with BBR3464, HSA fluorescence was shown to decrease 
over time with an approximate 16% decrease in overall fluorescence after 72hrs. 
(Figure 3.11A) The same trend in fluorescence decrease of HSA is also seen in the 
chemically modified HSA series.  Figure 3.11B shows the influence of the charged 
portion of drug binding on the overall conformation of the methionine blocked protein; 
with a decrease in fluorescence of approximately 17%.  The interaction of BBR3464 
with methionine blocked HSA in nearly identical as seen in native HSA, which shows a 
fluorescence decrease of 16%. Although not covalently bound to methionine blocked 
HSA, the charge portion of BBR3464 associates with the surface of the protein, causing 
perturbations in the global HSA structure.  The same trend is seen with the interactions 
of BBR3464 and cysteine blocked HSA, with an overall fluorescence decrease of 14%. 
(Figure 3.11C)  Therefore the decrease in fluorescence represents global changes in 
the structure of HSA upon BBR3464 electrostatically binding to the surface of albumin.  
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To this extent, fluorescence spectroscopy provides a means to analyze the effect of 
charge on the binding between HSA and PPC‟s, independent on the covalent or non-
covalent nature of the final platinum-protein adduct. 
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Figure 3.10 Charge density structure of human serum albumin with positive regions shown in blue and 
negative regions shown in red. Figure adapted from PDB ID: 1BM0 
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Figure 3.11  Electrostatic Effects on HSA Global Structure. BBR3464 was incubated with HSA, 
methionine blocked HSA, and cysteine blocked HSA for 0, 24, 48, and 72hrs.  Top spectrum represents 
protein before addition of BBR3464.  Bottom spectrum represents complex formed after 72hr reaction. 
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Conclusion  
In this contribution we examine the reactions of polynuclear platinum compounds 
with plasma and human serum albumin (HSA).  We show for the first time the presence 
of a pre-associated or “noncovalent” interaction of a platinum drug on the protein, as 
well as a method to possibly reduce drug protein interactions by ligand substitution. 
These studies suggest that the non-covalent compounds, AH44 and TriplatinNC may 
“by-pass” the deactivation associated with Pt–S bond formation. This is especially 
important for TriplatinNC as this 8+ compound is taken up into cells in a significantly 
greater concentration than either BBR3464 or AH44, and as a result has demonstrated 
in vitro cytotoxicity equivalent to cisplatin. The “non-covalent” compounds have shown a 
new mode of DNA binding distinct from intercalation and minor-groove binding. As 
these reactions with plasma, and especially with HSA, are generally considered 
responsible for the metabolic deactivation of platinum-based drugs, understanding the 
biophysical aspects of such interactions may allow for strategies to manipulate their 
extent with consequent effects on cellular uptake and even therapeutic index. 
 
Materials and Methods 
Materials 
All platinum compounds were synthesized according to methods reported previously. 
11,29-30 Human plasma was purchased from Innovative Research Inc. Dehydrated 
citrated mouse plasma and Albumin from human serum, minimum 99%, N-
ethylmaleimide, and Iodomethane, were obtained from Sigma-Aldrich (St. Louis, MO). 
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Mouse Plasma Binding 
Dehydrated citrated mouse plasma was purchased from Sigma Aldrich and 
reconstituted in accordance with the manufacturer‟s directions. Complex solutions were 
prepared in sterilized water and added to mouse plasma such that the final 
concentration of complex was 0.9 mM. The mixtures were reacted at 37 °C for 0, 0.5, 2 
and 24 hours in the dark, then centrifuged through a Microcon YM-10 10,000 kDa 
membrane filter at 14000 g for 10 min to isolate the ultrafiltrate. The centrifuge cup was 
upturned in a second eppendorf and then centrifuged at 1000 g for 3 min to isolate the 
protein-bound fraction. The samples were stored at -20 °C prior to digestion. Analysis 
was performed on a Varian ICP-OES.  
 
Human Plasma Binding 
Solutions of each drug were prepared in PBS and added to human plasma such that the 
final concentration of complex was 0.9mM (1:1 v/v).  The reactions were incubated at 
37 °C for 0, 0.5, 2 and 24 hours.  Unreacted drug was removed by centrifugation 
through a Millipore Microcon YM-10 (10,000 kDa) membrane filter at 14,000xg for 
30 min.  The centrifuge cup was upturned in a second eppendorf and centrifuged at 
1000xg for 3 min to isolate the protein-bound drug. Both ultrafiltrate and protein samples 
were stored at -20°C immediately following centrifugation. The digestion procedure 
followed published methods.29  Analysis of platinum content for both the protein-bound 
and unreacted samples was performed on a Varian ICP-OES. Protein concentration 
was determined by the Bradford method with human serum albumin as the standard.31 
 
81 
 
Human Serum Albumin Protocol 
1.8mM solutions of each complex were prepared in phosphate buffer and added to 0.6 
mM HSA such that the final concentration of complex was 0.9 mM. (3:1; complex:HSA)  
The mixture was reacted at 37 °C and 100μL aliquots were removed at t=0, 0.5, 2, 6, 
and 24 hours.  Aliquots were then centrifuged through a Microcon YM-10 10,000 kDa 
membrane filter as described above. 
 
HSA Protein Modification and Binding Site Evaluation 
Cys-34-blocked HSA was prepared by incubation of albumin solution in 100 mM 
ammonium bicarbonate, pH 7.9, with 2 mol eq of N-ethylmaleimide for 24 h at ambient 
temperature in the absence of light.  Methionine residues were methylated by reaction 
with iodomethane. Iodomethane in 500-fold molar excess was added to an HSA 
solution in 0.1 M citric acid-phosphate buffer, pH 4.0. The solutions were stirred at 
ambient temperature for 24 h in the dark. Blocking reagents were removed by 
centrifugation through a 10,000MW membrane filter.  Concentrated protein sample was 
then redissolved in ddH2O and lyophilized. 
 
Fluorescence Binding Studies with Chemically Modified HSA 
Fluorescence Binding Studies were performed on Native HSA, Cys-Modified HSA, and 
Met-Modified HSA in an attempt to determine the influence of amino acid availability on 
BBR3464 binding.  Fluorescence measurements were conducted on a Cary Eclipse 
Fluorimeter with the excitation and emission wavelengths set at 279 and 310 nm, 
respectively, with a scan rate 120 of nm min−1. The reactions of platinum compounds 
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were studied at 10:1 (Pt:HSA). An initial concentration for a 10:1 reaction was prepared 
for each drug. Separate measurements were taken at t = 0 and appropriate time 
intervals.   
 
Fluorescence Spectroscopy 
Fluorescence measurements were conducted on a Cary Eclipse Fluorimeter with the 
excitation and emission wavelengths set at 280 and 320 nm, respectively, with a scan 
rate of 120 nm/min. The reaction of TriplatinNC was studied at reactant ratio of 1:1 
(Drug:HSA). Each sample was allowed to react for the stated time at 37oC before the 
measurement was taken. Separate measurements were taken at t = 0 and appropriate 
time intervals. 
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Abstract 
Although the cytotoxic effects of clinical platinum based chemotherapeutics result 
mainly from damaging drug-DNA adducts, the overall efficacy of these drugs is limited 
by metabolic deactivation through covalent drug-protein binding. In this study the effects 
of glutathione, human serum albumin (HSA) and whole serum binding with cisplatin, 
BBR3464, and TriplatinNC, a “noncovalent” derivative of BBR3464 were investigated. 
Specifically, we ask whether these interactions can influence the efficacy of TriplatinNC, 
including cytotoxicity, levels of cellular accumulation, DNA adduct formation, and 
intracellular distribution. After 48 hours of treatment with buthionine sulphoximine 
(BSO), the cellular glutathione level was reduced and cisplatin and BBR3464-induced 
apoptosis was augmented. In contrast, TriplatinNC-induced cytotoxicity was unaltered 
by inhibiting glutathione synthesis. Treatment of A2780 ovarian carcinoma cells with 
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HSA bound cisplatin (cisplatin/HSA) and cisplatin pre-incubated with whole serum show 
dramatic decreases in cytotoxicity, cellular accumulation, and DNA adduct formation 
compared to treatment with cisplatin alone.  Treatment with HSA bound BBR3464 
(BBR3464/HSA) and BBR3464 pre-treated with whole serum also show a drastically 
reduced cytotoxic profile, and significantly less DNA platination.  In contrast, 
TriplatinNC, the HSA bound derivative (TriplatinNC/HSA), and TriplatinNC pre-treated 
with whole serum retained identical cytotoxic profiles and equal levels of cellular 
accumulation at all time points.  Confocal microscopy of TriplatinNC-NBD, a fluorescent 
derivative of TriplatinNC, and TriplatinNC-NBD/HSA both show nuclear/nucleolar 
localization patterns, distinctly different from the lysosomal localization pattern seen with 
HSA.  Cisplatin-NBD, a fluorescent derivative of cisplatin, was shown to accumulate in 
the nucleus and throughout the cytoplasm while the localization of Cisplatin-NBD/HSA 
was limited to lysosomal regions of the cytoplasm.  The results suggest that TriplatinNC 
can avoid high levels of metabolic deactivation currently seen with clinical platinum 
chemotherapeutics, and therefore retain a unique cytotoxic profile after cellular 
administration. 
 
Introduction 
Platinum drugs are among the most commonly used chemotherapeutics for the 
treatment of testicular, head and neck, ovarian, small cell lung, and colorectal 
carcinomas 1-3. The cytotoxicity of cisplatin is accepted to result mainly from the 
formation of bifunctional DNA crosslinks resulting in the inhibition of DNA synthesis and 
replication.4 The DNA-reactive platinum species are considered to be monoaquo and 
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diaquo complexes – in general [Pt(amine)2(H2O)2]
2+ or [Pt(amine)2(Cl)(H2O)]
+ -   
produced upon hydrolysis of the administered drugs, and the chemistry of these species 
has been well examined.5 While this concept has been useful in rationalizing some 
structure-activity relationships, there is increasing understanding that even anions with 
nominally weak affinity for platinum  – CO3
2- 6-7; SO4
2- 8; PO4
3- and even RCOO- 9  - 
become physiologically relevant ligands because of their high concentrations in plasma 
and cells. Similarly, cellular accumulation of platinum drugs is multifactorial with 
evidence for both passive and active transporter-mediated processes.10 
The three major pharmacological factors affecting the clinical success of any type 
of platinum-based cancer therapy are cellular uptake, the frequency and the type of 
DNA adducts formed and metabolic deactivation. Metabolic deactivation is also 
mediated through interactions of the small molecules with biomolecules, specifically 
sulfur-containing amino acids in proteins, and these interactions may contribute to the 
toxic side effects associated with platinum based treatments.11-12 One of the most 
plausible extracellular non-DNA targets for platinum compounds is blood serum. Serum 
is the liquid portion of blood, approximately 55% of the total volume, excluding red and 
white blood cells, containing all plasma proteins at a concentration of 70 g/L.13 These 
proteins include fibrinogen, globulins, and human serum albumin (HSA).  Albumin, the 
most abundant serum protein at 30-50g/L and the most likely protein candidate for drug 
metabolic interactions, is a 585 amino acid, 66 kDa, single chain protein involved in 
transportation of numerous drugs and ligands 14-15. It is mainly accepted that once 
coordinated to plasma proteins, platinum compounds are effectively „deactivated‟ and 
eliminated from the body; thus never reaching their desired site of action 16-17. 
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Another important sulfur-containing protein found intracellularly is the tripeptide, 
glutathione (GSH) 18.  The normal intracellular concentration of GSH ranges from 5 to 
10 mM 19, therefore the binding of platinum-containing drugs to GSH is highly probable. 
Cells with elevated glutathione (>10mM) are more resistant to cisplatin 20, indicating its 
clinical importance.  Due to these metabolic consequences resulting in low cellular Pt-
DNA binding, it is necessary to fully investigate the interactions of sulfur-containing 
biomolecules with current clinical and pre-clinical platinum chemotherapeutics. 
Polynuclear platinum compounds are a structurally discrete class of drugs whose 
chemical and biological properties differ significantly from cisplatin.21-23 BBR3464, the 
only non-cisplatin-like molecule to enter human clinical trials, and has promising activity 
in cisplatin-resistant, cisplatin-sensitive and p53 mutant tumors.24-26  BBR3464 is also 
forty to eighty fold more potent on a molar basis than cisplatin.27  Promising pre-clinical, 
Phase I and Phase II clinical studies of BBR3464 have been offset to some extent by 
rapid degradation of BBR3464 into inactive metabolites due to enhanced interactions 
with plasma proteins.28-29 The production of these inactive metabolites may be 
replicated by the chemical reactions of BBR3464 with reduced GSH.18 These 
pharmacokinetic factors are thought to contribute to reduced activity in gastric and lung 
cell carcinomas 30-31.  For the development of subsequent generations of platinum 
derivatives, it is necessary to design platinum compounds which may have the ability to 
avoid or minimize these metabolic deactivations.   
Most platinum chemotherapeutics bind to DNA in a covalent manner by formation 
of a Pt-DNA adduct.  Replacement of the chloride leaving groups of BBR3464 with 
substitutionally „inert‟ ammine ligands or „dangling‟ ammines, H2N(CH2)6NH3
+, gives 
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„non-covalent‟ polynuclear platinum compounds; most notably TriplatinNC, Figure 4.1.  
Although chemically non-reactive, TriplatinNC binds to DNA through the formation of a 
„phosphate clamp‟, a ligand mode of binding distinct from the “classical” minor-groove 
binders and intercalators.32  TriplatinNC has significantly higher cellular accumulation 
than either BBR3464 or cisplatin, and in some cases equivalent or greater cytotoxicity 
than cisplatin.33-34  
Biophysical studies on the interaction of TriplatinNC with albumin have shown the 
presence of an initial, electrostatic, association with the protein.35  Previous studies 
have shown that the interactions of cationic lipids with albumin give approximate binding 
ratios of 1-2:1 (Lipid:Albumin).36 Due to its‟ high charge, TriplatinNC would be expected 
to associate to albumin and other serum proteins in vivo, but in the absence of a 
substitution-labile leaving group, would not be expected to undergo the same types of 
deactivation reactions as seen with the covalent platinum analogs. 12,17,35  This protein 
association, in the absence of deactivation, could provide a promising and novel 
pharmacokinetic profile not seen in current clinical platinum regiments. This paper 
addresses the effects of serum protein and glutathione deactivation on platinum drug 
trafficking and the consequences for compound efficacy, levels of cellular accumulation, 
DNA adduct formation, and intracellular distribution. The effects of protein association 
on intracellular localization were examined by confocal microscopy using a new, 
versatile fluorophore for platinum drugs based on 7-nitro-2,1,3-benzoxadiazole (NBD). 
 
Results and Discussion 
Importance of Glutathione in TriplatinNC Mediated Cytotoxicity 
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One of the main intracellular biomolecules is glutathione (GSH), which has an 
important role in determination of cellular sensitivity to cytotoxic drugs. (Figure 4.1A)  
The cellular glutathione level in HCT116 cells was decreased using buthionine 
sulphoximine (BSO), which inhibits gamma glutamylcysteine synthetase, a rate limiting 
enzyme in glutathione synthesis.37-38  As the cellular glutathione level was reduced, 
cisplatin, and BBR3464-induced apoptosis was augmented, demonstrating their 
interactions with glutathione.  After 48 hours of treatment, BSO alone and BBR3464-
induced apoptosis were 1% and 18% (as in control sample), but the combination of 
BBR3464 and BSO increased apoptosis to 58% (Figure 4.1B). The results showed 
consistency in testing with cisplatin.  BSO increased cisplatin-induced apoptosis from 
14% to 45% (Figure 4.1B).  In striking contrast to these covalent Pt drugs, TriplatinNC-
induced cytotoxicity was completely unaltered by inhibiting glutathione synthesis. 
(Figure 4.1B) 
Since some efflux mechanisms have been shown to be dependent on glutathione 
39, the effects of BSO on the cellular accumulation of platinum drugs was measured. 
Cellular platinum levels were measured via ICP-OES in cells treated with platinum 
drugs +/- BSO to determine if the increase observed in cytotoxicity is the result of 
enhanced cellular uptake of platinum drugs. As shown in Figure 4.1C, BSO did not 
influence cisplatin, BBR3464, or TriplatinNC cellular accumulation. Hence, cellular 
accumulation does not play a role in the augmentation of Pt-induced cytotoxicity by 
BSO. 
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Figure 4.1 (A) Chemical structures of cisplatin (top), BBR3464 (middle) and TriplatinNC (bottom). (B) 
Effect of BSO on platinum drug-induced cytotoxicity in HCT116 cells.  Sub-diploid cell content was 
detected by PI-DNA staining.  HCT116 cells were cultured with 10µM cisplatin, 50µM BBR3464,, or 40µM 
TriplatinNC for 48h in the absence or presence BSO. Drugs were added to the media after 1h of 
treatment with BSO. (C) Effect of BSO on platinum drug cellular uptake in HCT116 carcinoma cell lines. 
HCT116 cells were cultured with 20µM cisplatin for 16h, 20µM BBR3464 for 8h, or 20µM TriplatinNC for 
3h in the absence or presence of 500µM BSO. Drugs were added to the media after 1h of treatment with 
BSO. Each point represents the average (+/- SEM) of three independent experiments. 
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Effects of Protein Binding on Cisplatin, BBR3464, and TriplatinNC 
The pharmacokinetic profiles in Phase I clinical trials of BBR3464 and cisplatin 
have been shown to be vastly different, with protein binding in BBR3464 being much 
higher than cisplatin at early time points.27 To evaluate the effect of protein binding on 
drug deactivation, cisplatin, BBR3464 and TriplatinNC were incubated with human 
plasma or human serum albumin for selected time points. Analysis of platinum content 
by ICP-OES shows an increase in protein binding over time for both cisplatin and 
BBR3464 after incubation with whole serum.  This time dependent increase in protein 
binding represents a displacement of the platinum-chloride bond and the formation of 
the covalent platinum-protein adduct. (Figure 4.2) In contrast, with the non-covalent 
compound, TriplatinNC, a 1:1 drug protein complex is immediately formed, representing 
a rapid association of the positively charged drug, presumably with negative regions of 
serum proteins.(Figure 4.2) Due to the chemical nature of TriplatinNC, the initial non-
covalent binding is not followed by covalent drug–protein adduct formation. 
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Figure 4.2 Effects of protein binding on free drug availability of cisplatin, BBR3464, TriplatinNC. Final 
binding ratio of platinum compounds to human plasma over time. 
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Role of Protein Binding on Cytotoxicity of Cisplatin, BBR3464, and TriplatinNC 
In theory, once a covalent platinum-protein adduct is formed, the drug “loses” its 
cytotoxic effect and is rendered inactive.40 To further understand the differences in 
binding profile between covalent and „non-covalent‟ platinum compounds with HSA, 
cytotoxicity assays were performed on the protein bound derivatives of cisplatin, 
BBR3464, and TriplatinNC (cisplatin/HSA, BBR3464/HSA, and TriplatinNC/HSA) and 
compared to the free drug IC50 values in A2780 ovarian carcinoma cell lines.  As seen in 
Figure 4.3A, A2780 cells treated with cisplatin/HSA show a large decrease in drug 
efficacy as compared with treatment of cisplatin alone. The same trend can be seen 
with BBR3464/HSA and BBR3464. (Figure 4.3B)  In stark contrast, A2780 cells showed 
no change in growth inhibition when treated with the complex TriplatinNC/HSA 
(IC50≈3µM) as compared to treatment of the drug alone, TriplatinNC (IC50≈3µM). (Figure 
4.3C) 
Incubation of cisplatin, BBR34364 and TriplatinNC with whole serum provides a 
physiological approach to studying the effects of protein binding on drug efficacy.   
Cisplatin and BBR3464 both show a time-dependent decrease in cytotoxicity upon 
incubation followed by cellular exposure after pretreatment with serum.  (Figure 4.3 D, 
E) For cisplatin and BBR3464, the observed IC50 values decreased from 0.6µM to 
>30µM, and 0.2µM to >30µM respectively over a 72 hour period. Cellular treatment with 
TriplatinNC after 72hr media incubation showed no marked decrease in IC50 value, 
remaining approximately 3µM at all timepoints. (Figure 4.3F). 
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Figure 4.3 Influence of protein binding on platinum drug efficacy in A2780 ovarian carcinoma cells.  (A) 
Cisplatin cytotoxicity (▲) in A2780 cells compared with the treatment of cisplatin/HSA (■). (B) BBR3464 
cytotoxicity (▲) compared with the treatment of BBR3464/HSA (■). (C) TriplatinNC cytotoxicity (▲) 
compared with the treatment of TriplatinNC/HSA (■). (D-F) Platinum compounds were incubated with 
serum supplemented media for 0-72hrs.  Cellular grown inhibition was then measured after treatment.  
Efficacy of cisplatin (D), BBR3464 (E), and TriplatinNC (F) following increased serum incubation times (0-
72hrs).  A2780 cells were cultured in the indicated concentrations of each compound for 72h. Percent 
growth inhibition was determined by comparing live cell numbers in treated and untreated cultures after 
72h, as measured by MTT. Values are the average (+/- S.E.M.) of three independent experiments.  
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Effects of Protein Binding on Cellular Drug Accumulation 
Since the rate of cellular uptake and total accumulation correlates to the cytotoxic 
effect of platinum drugs, cellular accumulation of each platinum compound and its 
protein bound derivative was examined at IC90 concentrations, Figure 4.4. Treatment of 
A2780 cells with cisplatin produced an increase in cellular platinum levels in a time 
dependent manner, reaching approximately 30 attomole Pt/cell after 24hrs.  In contrast, 
cells treated with cisplatin/HSA showed a drug accumulation of 5 attomole Pt/cell or less 
at all time points. (Figure 4.4A)  Cellular treatment with BBR3464 also shows a time 
dependent increase in drug concentration, reaching approximately 100 attomole Pt/cell 
after 24hrs.  (Figure 4.4B) In contrast to cisplatin/HSA, the protein bound derivative of 
BBR3464 shows a sporadic increase in platinum concentration over time.  Although 
BBR3464 is covalently bound to albumin, the chemical nature of this binding may cause 
the tri-nuclear drug to degrade into di-nuclear and mononuclear non-covalent, non-
cytotoxic metabolites as seen previously with the treatment of blood cells with 
BBR3464. 18,29,41  It is reasonable to assume that these di-nuclear and mononuclear 
metabolites may also enter cells and contribute to the measurement of Pt levels.  In 
contrast, platinum accumulation in cells treated with TriplatinNC and TriplatinNC-HSA 
was nearly identical at all time points, reaching approximately 400 attomole Pt/cell at the 
24hr timepoint. (Figure 4.4C) Note again the enhanced accumulation of charged 
trinuclear drugs in comparison to cisplatin. 
 To examine the role of whole serum deactivation on the rate of cellular 
accumulation levels for cisplatin, BBR3464 and TriplatinNC, intracellular platinum levels 
were determined after 24 hours of drug exposure, following specified serum incubation 
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times.  Treatment of cisplatin with serum supplemented media shows a time-dependent 
decrease in cellular platinum uptake following drug exposure for 24 hours. (Figure 4.4D) 
Treatment of BBR3464 with serum supplemented media shows a constant level of 
cellular platinum uptake following drug exposure for 24 hours. This platinum 
accumulation is interpreted to correspond to a mixture of the covalent and non-covalent 
metabolites of BBR3464, consistent with the metabolic degradation seen after protein 
binding. (Figure 4.4E) Upon incubation with serum for 24, 48, and 72 hours and 
subsequent cellular treatment, TriplatinNC cellular accumulation levels remains 
constant. (Figure 4.4F) A constant IC50 value over time and a consistent rate of cellular 
drug accumulation shows the ability of TriplatinNC to “by-pass” the typical protein 
deactivation pathway seen with current platinum chemotherapeutics. 
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Figure 4.4 Influence of protein binding on platinum cellular uptake in A2780 ovarian carcinoma cells. 
A2780 Cells were treated with IC90 concentrations of cisplatin and cisplatin/HSA (A), BBR3464 and 
BBR3464/HSA (B), TriplatinNC and TriplatinNC/HSA (C) for 0, 3, 6, 12, and 24 hours. For serum 
incubation studies each platinum drug was pre-incubated with serum for (0-72hrs).  A2780 cells were 
then treated with IC90 concentrations of each compound ((D) Cisplatin, (E) BBR3464, (F) TriplatinNC) for 
24hrs. After appropriate incubation times, cells were removed from the plate and washed with PBS. 
Analysis of platinum content was performed on a Varian ICP-MS. Values are the average (+/- S.E.M.) of 
three independent experiments. 
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Effects of Protein Binding on Levels of DNA Platination 
 The cytotoxicity of platinum chemotherapeutics is mainly accepted to be 
modulated by the frequency and type of platinum-DNA adducts formed during drug 
treatment.  To examine the role of protein binding on the amount of DNA platination, 
A2780 cells were treated for 24hrs with IC90 concentrations of cisplatin, cisplatin/HSA, 
BBR3464, and BBR3464/HSA.  DNA platination levels after 24 hours of continuous 
cisplatin treatment reached approximately 225 nmole Pt/g DNA, while platinum levels of 
cisplatin/HSA remained less than 10 nmole Pt/g DNA. (Figure 4.5A) The same trend in 
DNA adduct formation was seen with BBR3464 and BBR3464/HSA, with platinum 
levels reaching 425 and 20 nmole Pt/g DNA respectively. (Figure 4.5B) 
 DNA platination levels of cisplatin and BBR3464 were also monitored following 
serum incubation.  After incubation with serum proteins for 24, 48, and72hrs, both 
cisplatin and BBR3464 DNA platination levels were reduced.  Initial levels of DNA 
platination for cisplatin were approximately 225 nmol platinum / g DNA.  After 72hrs of 
serum treatment prior to cell treatment, DNA platination levels were reduced to 31 nmol 
platinum / g DNA. (Figure 4.5C) The same trend was seen with serum pre-treatment of 
BBR3464, where platinum levels decrease from 425 nmol platinum / g DNA to 230 nmol 
platinum / g DNA. (Figure 4.5D) The decreases in DNA platination seen after protein 
binding are directly responsible for the reduced activity of both cisplatin and BBR3464. 
Due to the non-covalent nature of TriplatinNC-DNA binding 32, isolation of cellular 
DNA may disrupt the interaction. To resolve this inherent problem, we have developed a 
new fluorescent probe for platinum and used fluorescence microscopy as a tool to 
examine the effects of protein binding on cellular distribution and DNA platination.  
102 
 
 
Figure 4.5 Influence of protein binding on DNA platination in A2780 ovarian carcinoma cells. A2780 Cells 
were treated with IC90 concentrations of cisplatin and cisplatin/HSA (A), BBR3464 and BBR3464/HSA for 
24 hours. For serum incubation studies each platinum drug was pre-incubated with serum for (0-72hrs). 
A2780 cells were then treated with IC90 concentrations of each compound ((C) Cisplatin, (D) BBR3464) 
for 24hrs. After appropriate incubation times, cells were removed from the plate and washed with PBS. 
Cellular DNA was then extracted and analysis of platinum content was performed on a Varian ICP-MS. 
Values are the average (+/- S.E.M.) of three independent experiments. 
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Fluorescent Drug Design of TriplatinNC-NBD and Cisplatin-NBD 
The use of molecular imaging techniques, such as confocal microscopy, is an 
important tool in the understanding of platinum drug trafficking and intracellular 
distribution. To utilize this approach, new fluorescent platinum derivatives were 
developed using NBD fluorophores. Hambley has summarized recent fluorescent 
approaches to monitoring platinum trafficking.42 The advantage of the NBD approach is 
that rather than use chelates like ethyelenediamine and cumbersome chemical 
modifications, the NBD addition is performed on a primary amine and gives analogs 
very similar to the “parent drugs”. Previous attempts at “tagging” platinum compounds 
have yielded cisplatin derivatives in which FITC and Alexa based fluorophores have 
been utilized. These derivatives tend to mimic the biological properties of the 
fluorescent “tag” rather than the platinum moiety itself. 42  In the case of TriplatinNC, we 
conjugated the NBD fluorophore directly to the primary amine on each end of the 
complex, and for cisplatin, we replace the existing amine group with NBD-ethane-1,2-
diamine.  TriplatinNC-NBD shows only a 12% increase in molecular weight, retains a 
high positive charge (6+), and shows similar cytotoxicity to TriplatinNC. (Figure 4.6A) 
Cisplatin-NBD has a molecular weight increase of 66%, substantially less than seen 
with FDDP 42, and also retains a cytotoxic profile in A2780 cells. (Figure 4.6B) 
 
Role of Albumin in the Cellular Localization of Cisplatin and TriplatinNC 
The mechanisms of cellular uptake and distribution of albumin and other serum 
proteins have been extensively studied and show that serum proteins localize to 
lysosomal regions of the cytosol.43 The use of a non-covalent drug, TriplatinNC, affords 
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a unique handle to examine how macromolecule association affects small platinum 
molecule biodistribution – in the absence of platinum bond-forming reactions. Confocal 
microscopy was therefore employed to investigate how internalization and localization 
of cisplatin and TriplatinNC is affected by albumin.  A2780 cells were treated with 
cisplatin-NBD (15µM) and cisplatin-NBD/HSA (1mg/mL) to investigate the role of 
covalent protein binding on drug localization. LysoTracker® Red was used as a 
lysosomal marker to indicate uptake of HSA. (Figure 4.7) Cisplatin-NBD was shown to 
localize throughout the cytosol and, to a lesser extent, the nucleus. (Figure 4.8A) This 
distribution is consisted with the fact that less than 10% of cellular cisplatin is found in 
the nucleus. After treatment of cisplatin-NBD/HSA, the cytosolic and nuclear localization 
was significantly reduced and limited to lysosomal regions of the cytosol. Co-localization 
of cisplatin-NBD/HSA and LysoTracker® Red was seen at a greater extent than with the 
treatment of cisplatin alone, indicating an increase in drug deactivation after protein 
binding. 
HSA (1mg/mL) and TriplatinNC-NBD (15µM) (Protein:Drug, 1:1) were pre-
incubated in serum-free media for 2hrs to ensure complex formation.  Upon treatment 
with TriplatinNC-NBD/HSA for 6hrs, punctate cellular localization of LysoTracker® Red 
was observed in a pattern consistent with lysosomal accumulation while TriplatinNC 
was shown to localize throughout the cytosol and nucleolus.  The uptake of TriplatinNC-
NBD alone was shown to be identical to the localization seen upon treatment of the 
protein bound complex. (Figure 4.8B) The difference in accumulation patterns between 
TriplatinNC and LysoTracker® Red, and more importantly, the similarity between 
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TriplatinNC-NBD and TriplatinNC-NBD/HSA localization, show the ability of TriplatinNC 
to avoid metabolic deactivation associated with serum binding. 
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Figure 4.6 MTT cytotoxicity assay of fluorescent platinum derivatives, TriplatinNC and TriplatinNC-NBD 
(A) and cisplatin and cisplatin-NBD (B) 
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Figure 4.7 Confocal laser scanning micrographs of A2780 cells. After incubation with FITC-albumin 
(1mg/mL) for 1hr and with LysoTracker
®
 Red (75 nM) for 30 min at 37
o
C, cells were fixed and observed 
by confocal laser scanning microscopy.  (left) LysoTracker
®
 Red (red) + DAPI (blue) (B) FITC-albumin 
(green), (C) merged (A+B). A2780 Cells were grown on 4-well chamber slides (Lab-TekII Chamber Slide) 
for 2-3 days until cells reached near-confluency.  Cells were then incubated with FITC-albumin (1 mg/mL) 
for 60 min, and with LysoTracker
®
 Red (75 nM) for 30 min at 37
o
C. After treatment, slides were washed 
3x with ice-cold PBS and fixed with 3% paraformaldehyde.  Paraformaldehyde was removed and cells 
were washed again with 3x PBS and allowed to dry.  Slides were then mounted with Vectashield 
mounting media containing DAPI.  Fluorescence was observed by confocal laser scanning microscopy 
(Zeiss LSM 510). 
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Figure 4.8 Role of protein binding on the cellular localization and distribution of cisplatin and TriplatinNC.  
Confocal laser scanning micrographs (A-B) of A2780 cells.  (A) (top row) Cisplatin-NBD (15uM) (green) 
incubated with A2780 cells for 24hrs and LysoTracker Red
®
 (75nM) (red) for final 30min of drug 
incubation.  (A) (bottom row) Cisplatin-NBD/HSA (1mg/mL) (green) incubated with A2780 cells for 24hrs 
and LysoTracker Red
®
 (75nM) (red) for final 30min of drug incubation.  Orange color represents areas of 
drug-protein co-localization. (B) (top row) TriplatinNC-NBD (15uM) (green) incubated with A2780 cells for 
6hrs and LysoTracker Red
®
 (75nM) (red) for final 30min of drug incubation. (B) (bottom row) TriplatinNC-
NBD/HSA (1mg/mL) (green) incubated with A2780 cells for 6hrs and LysoTracker Red
®
 (75nM) (red) for 
final 30min of drug incubation.  Orange color represents areas of drug-protein co-localization. Slides were 
mounted with Vectashield mounting media containing DAPI (blue).  Fluorescence was observed by 
confocal laser scanning microscopy (Zeiss LSM 510). (C) Chemical structures of TriplatinNC-NBD (top) 
and Cisplatin-NBD (bottom). 
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Conclusion 
This study shows, for the first time, a platinum chemotherapeutic with a 
substantially enhanced and distinctly different pharmacokinetic profile than that of any 
clinically developed platinum drug. This work has shown the significance of the 
interaction of TriplatinNC with plasma as well as individual intracellular and extracellular 
proteins.  The non-covalent binding of TriplatinNC to serum proteins allows for an 
interaction with the protein, but not a deactivation of the platinum compound. The 
deactivation of cisplatin and BBR3464 upon binding to glutathione, serum or albumin 
show the major problems associated with the treatment of cancer using the current 
platinum chemotherapeutic regiment. 
The data also allows one to examine the role of albumin as a drug carrier or drug 
delivery system for TriplatinNC. Albumin is known to function as an important protein in 
the maintenance of osmotic pressure and also as a transport protein involved in the 
distribution of hormones, fatty acids and metal ions.44-45 Once administered, TriplatinNC 
would be expected to bind to plasma proteins in a non-covalent manner and then be 
transported to the cellular surface or become actively transported internally through the 
endocytosis of albumin.43 The mechanism of uptake of TriplatinNC and the role of 
albumin in this process was examined by utilizing novel fluorescently labeled derivatives 
of both cisplatin and TriplatinNC. Further, the non-covalent drug is a unique probe for 
studying platinum drug molecule-biomolecule interactions in cells. TriplatinNC not only 
presents a new mode of DNA binding, distinct from any clinical platinum agent, but also 
allows for the elimination of covalent Pt-protein adduct formation, thus creating a novel 
pharmacokinetic and cytotoxicity profile worthy of further development. 
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Materials and Methods 
Materials 
BBR3464, cisplatin, and TriplatinNC were synthesized according to methods reported 
previously. 46-48 Synthesis of TriplatinNC-NBD and Cisplatin-NBD is described in the 
methods section. Human plasma was purchased from Innovative Research Inc. 
Albumin from human serum, minimum 99%, FITC-Albumin, and Buthionine 
sulphoximine (BSO) was obtained from Sigma-Aldrich (St. Louis, MO). LysoTracker® 
Red DND-99 was obtained from Invitrogen and recombinant HSA (rHSA) was a 
generous gift from Delta Biotechnologies. 
 
Synthesis of Cisplatin-2-NBD and TriplatinNC-NBD 
N-(7-nitro-2,1,3-benzoxadiazol-4-yl)hexane-1,6-diamine. Ligand was synthesized by 
a modification of a described procedure.49 BOC–diaminohexane hydrochloride was 
dissolved in ddH20 and NBD-Cl (5eq) and DIPEA (2eq) was added. After the mixture 
had been stirred at room temperature overnight the product was extracted with diethyl 
ether. The organic phase was washed with brine (4x10 mL), dried over Na2SO4 and 
purified by flash chromatography (CHCl3/EtOAc, 90:10). The BOC protecting group of 
the purified intermediate was removed by using trifluoroacetic acid (1 mL) at room 
temperature. After the mixture had been stirred overnight, excess TFA was evaporated, 
and the oily product was treated with diethyl ether to yield the product as orange 
crystals. 
N-(7-nitro-2,1,3-benzoxadiazol-4-yl)ethane-1,2-diamine (L): BOC–diaminoethane 
(0.79 ml, 4.99 mmol) was dissolved in 20 ml ethanol containing a 10% w/w of Na2CO3, 
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and NBD-Cl (0.50 g, 2.51 mmol) was added. The mixture was stirred at room 
temperature overnight, then 50 ml of water were added and the product was extracted 
with diethyl ether (3 x 30 ml). The organic phase was washed with brine (3 x 30 ml), 
dried over Na2SO4 and purified by flash chromatography (CHCl3/EtOAc, 70:30). The 
BOC protecting group of the purified intermediate was removed by using 2 ml of 
trifluoroacetic acid at room temperature. After the mixture had been stirred overnight, 
excess TFA was evaporated, and the oily product was treated with diethyl ether to yield 
the trifluoroacetate salt as orange crystals.  
Both ligands were neutralized by dissolving in a mixture of H2O/Ethanol 1:1 and addition 
of 1 equivalent of NaOH. The neutral ligand was then extracted with CH2Cl2. The 
organic fractions were dried over K2CO3 and the solvent removed under vacuum. The 
product was dried under vacuum overnight. 
TriplatinNC-NBD2: BBR3464 Cl
- salt was treated with 5.97eq of AgNO3 in ddH20 and 
allowed to stir at room temperature for 4hrs.  AgCl was filtered off and to the clear 
solution was added NBD-diaminohexane (5eq) and DIPEA (5eq).  The solution was 
allowed to stir at 50oC overnight.  The solution was then evaporated to dryness and the 
resulting orange oil was re-dissolved in ddH20 and excess NBD-diaminohexane was 
removed by extraction with EtOAc (5x50 mL).  The aqueous layer was removed and the 
product was redissolved in ddH20 and lyophilized.  The resulting orange powder was 
washed with EtOAc, CHCl3 and diethyl ether to yield TriplatinNC-NBD2 (1.7mg, 30%)  
1H NMR D2O δ (ppm):  8.54 (d, 2H); 6.23 (d, 2H); 3.00 (t, 12H); 2.72 (m, 4H); 1.67 (m, 
16H); 1.42 (m, 16H). 
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Cis-[PtCl2((N-NBD)ethane-1,2-diamine)(NH3)]: The synthesis of this compound was 
achieved by means of a modification of a patented procedure50. K[PtCl3(NH3)] (30.0 mg, 
0.084 mmol) was dissolved in 5 ml of a 15 mM aqueous solution of KCl. A solution of KI 
(41 mg, 0.248 mmol) in 1 ml of water was prepared. The KI solution was added to the 
K[PtCl3(NH3)] solution, followed by a slight excess of the NBD amino ligand L (20.5 mg, 
0.091 mmol). The combined solution was stirred in the dark for 5 h at room temperature. 
A redish precipitate formed which was collected, washed with cold water, cold 
methanol, and dried under vacuum at room temperature overnight. The product was 
Cis-[PtI2((N-NBD)ethane-1,2-diamine)(NH3)], confirmed by NMR. The Cis-[PtI2((N-
NBD)ethane-1,2-diamine)(NH3)] (40 mg, 0.067 mmol) was suspended in 2 ml of a 
mixture H2O/Acetone 85:15 and 1eq of silver nitrate was added to the suspension. It 
was then stirred for 24 h in the dark at room temperature. The suspension was filtered 
and 200 ml of HCl (˜12 M) were added to the filtrate. The solution was stirred at room 
temperature for 2 h, during which time a black precipitate formed. The precipitate was 
filtered and the solution concentrated to obtain the product as a brownish powder, which 
was washed with ice cold methanol, ether and dried under vacuum. 1H NMR D2O δ 
(ppm):  8.45(d, 1H); 6.33 (d, 1H); 3.81 (t, 2H); 3.27 (t, 2H). ESI-MS: m/z: (M+H)+ 507.22; 
(M-Cl)+ 471.23 
 
Cell System 
The colorectal carcinoma cell lines HCT116 were the kind gift of Bert Vogelstein (Johns-
Hopkins University, Baltimore, MD).  HCT116 and A2780 cells were cultured in RPMI 
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1640 with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin in 
humidified air with 5% CO2. 
 
Human Plasma Binding 
Solutions of each drug were prepared in PBS and added to human plasma such that the 
final concentration of complex was 0.9mM (1:1 v/v).  The reactions were incubated at 
37 °C for 0, 0.5, 2 and 24 hours.  Unreacted drug was removed by centrifugation 
through a Millipore Microcon YM-10 (10,000 kDa) membrane filter at 14,000xg for 
30 min.  The centrifuge cup was upturned in a second eppendorf and centrifuged at 
1000xg for 3 min to isolate the protein-bound drug. Both ultrafiltrate and protein samples 
were stored at -20°C immediately following centrifugation. The digestion procedure 
followed published methods.47  Analysis of platinum content for both the protein-bound 
and unreacted samples was performed on a Varian ICP-OES. Protein concentration 
was determined by the Bradford method with human serum albumin as the standard.51 
 
Formation of Drug-Albumin Complex 
Platinum compounds (Cisplatin, Cisplatin-NBD, BBR3464, and TriplatinNC) were 
incubated with HSA for 72hrs at 10:1(Drug:Protein). Non-protein bound drug was 
removed by centrifugation using method described above.  The protein was collected, 
redissolved in 5mL PBS and immediately frozen at -20oC.  Pt concentration was 
determined using ICP-OES by removing a small aliquot of the Pt-protein solution before 
freezing.  Protein concentration was determined by the Bradford method with human 
serum albumin as the standard.51 
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BSO Treatement, Propidium Iodide DNA Staining, and Analysis of Apoptosis 
HCT116 cells were cultured in 6-well plates at an initial density of 7.0 × 104 cells/ml.  
Different concentrations of drugs were added to each well as indicated.  Total cell 
contents (apoptotic and viable cells) were collected. In experiments using BSO, Pt drug 
concentrations were adjusted to achieve approximately 15%-20% apoptosis, allowing 
us to measure enhancement or inhibition. Samples were fixed in an ethanol and fetal 
bovine serum solution, washed with PBS, and stained with a solution of propidium 
iodide (PI) and RNase A, as described previously 52.  Samples were then analyzed for 
subdiploid DNA content on a Becton Dickinson FACScan flow cytometer (BD 
Biosciences, San Jose, CA).  It is noteworthy that this protocol differs significantly from 
the more common PI-based exclusion, which only differentiates live versus dead cells. 
Through fixation and RNase A treatment, we were able to detect intact versus 
fragmented DNA, revealing discrete stages of the cell cycle and the percentage of the 
population undergoing apoptosis. 
 
Cellular Growth Inhibition 
The MTT assay was used to determine growth inhibition potency of platinum drugs and 
the corresponding protein bound derivatives.53  A2780 cells were seeded in 96-well 
plates at 6,500 cells/well in 200μL of RPMI 1640 media and allowed to attach overnight. 
Media was removed and 200µL of each compound was added after serial dilution in 
quadruplicate wells and exposed to cells for 72h.  For time dependent media incubation 
studies 500µM of each Pt compound was incubated in RPMI 1640 media supplemented 
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with 10% FBS (1:1 v/v) for 0, 24, 48, and 72hrs before cellular treatment.  Samples 
were diluted to treatment concentrations [30µM – 0.25µM] with fresh media after 
appropriate time points and cells were treated accordingly.  Plates were then washed 
with PBS and 100µL of 5mg/mL MTT solution was added.  MTT solution was incubated 
with cells for 3h at 37oC. After incubation, MTT solution was removed and 100µL of 
DMSO was added.  Quantification of cell growth in treated and control wells was then 
assessed by measurement of absorbance at 562nm. IC50 values were determined 
graphically. 
 
Cellular Uptake of Drug and Drug-HSA Complexes 
A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to attach 
overnight. Cells were then treated with IC90 concentrations of each drug and drug-HSA 
complex,15 μM for TriplatinNC, 4µM for Cisplatin, and 2.5µM for BBR3464, in 15mL 
media for 0, 3, 6, 12, and 24 hours. After appropriate incubation times, cells were 
removed from the dish with trypsin and centrifuged for 5min at 1000xg. Media was 
removed, cell pellet was washed three times with PBS, cells were counted and 
resuspended in 250μL of ddH20.  Samples were then digested following published 
methods.47  Analysis of Pt content was performed on a Varian ICP-MS. Standards and 
blank were prepared similarly. 
 
Quantification of DNA-Drug Adducts 
A2780 cells were plated in 10cm dishes at 2 million cells/dish and allowed to attach 
overnight. Cells were then treated with IC90 concentrations of each drug and drug-HSA 
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complex, 4µM for Cisplatin, and 2.5µM for BBR3464, in 15mL media for 24 hours.  For 
time dependent media incubation studies 500µM of each Pt compound was incubated in 
RPMI 1640 media supplemented with 10% FBS (1:1 v/v) for 0, 24, 48, and 72hrs before 
cellular treatment.  After incubation, cells were removed from the dish with trypsin and 
centrifuged for 5min @ 1000xg. Media was removed and cell pellet was washed three 
times with PBS and suspended in 200μL of ddH20.  DNA was extracted using a DNeasy 
blood and tissue kit (Qiagen) according to the manufacturer‟s protocol.  Extent of DNA 
platination was measured on a Varian ICP-MS. 
 
Confocal Laser Scanning Microscopy of A2780 Cells 
A2780 Cells were grown on 8-well chamber slides (Lab-TekII Chamber Slide) for 2-3 
days until cells reached near-confluency.  A2780 cells were treated with cisplatin-NBD 
(15µM) and cisplatin-NBD/HSA (1mg/mL) for 24hrs.  LysoTracker® Red (75nM) was 
added to the slide for the final 30 minutes of drug treatment time.  For TriplatinNC-NBD 
(15µM) and TriplatinNC-NBD/HSA (1mg/mL), and FITC-Albumin (1mg/mL), A2780 cells 
were treated for 6hrs and LysoTracker® Red (75nM) was added to the slide for the final 
30 minutes of drug treatment time. After treatment, slides were washed 3x with ice-cold 
PBS and fixed with 3% paraformaldehyde.  Paraformaldehyde was removed and cells 
were washed again with 3x PBS and allowed to dry.  Slides were then mounted with 
Vectashield mounting media containing DAPI.  Fluorescence was observed by confocal 
laser scanning microscopy (Zeiss LSM 510). 
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Introduction 
Platinum drugs continue playing a prominent role in the treatment of cancer and 
are administered in around 50% of diagnosed patients.1-3 Cisplatin remains the most 
used inorganic antitumor drug to date. The cytotoxicity of cisplatin is accepted to result 
mainly from the formation of bifunctional 1,2-intrastrand DNA crosslinks with purine 
bases,  resulting in the inhibition of DNA synthesis and replication.4 Unfortunately the 
success of cisplatin based chemotherapeutics is limited due to eventual acquired drug 
resistance and a limited range of tumor types that are treatable with the current regime.  
Therefore, the present research motivation is to find new platinum based drugs which 
exert a uniquely distinct mode of DNA binding.  
Although the trans isomer of cisplatin, transplatin, remains clinically inactive, 
platinum compounds possessing a trans geometry became a new alternative when 
Farrell et al. reported the first examples of trans compounds with a higher potency than 
the respective cis isomers.5-7 It is now well established that the substitution in the 
inactive transplatin of one NH3 group by different families of amines, „activates‟ these 
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compounds, producing cytotoxicity values higher than their cis counterparts and, in 
many cases, equivalent to that of cisplatin.5-6 Two of the most common strategies in the 
synthesis of such compounds are the replacement of one NH3 by a planar ligand, 
typically a heterocyclic amine or aliphatic primary amine. Because the structure of the 
DNA adducts determines repair, protein recognition and other crucial cellular processes, 
it is widely accepted that the distinct platinum-DNA adducts that are formed when trans 
compounds interact with DNA are key for their potential therapeutic effectiveness. One 
possible explanation for the cytotoxic activity, especially for trans-platinum compounds 
containing heterocyclic derivatives, is the enhanced intercalation or pi-stacking seen 
between nucleobases on DNA and the aromatic heterocyclic amines on the platinum 
compound.  This interaction provides for a pseudo bi-functional adduct, similar to the 
cisplatin-DNA adducts.5 
The idea of a platinum compound that possesses a dual-mode of DNA binding 
has been slightly explored through the use of DNA intercalators conjugated to 
cisplatin.8-10  Although somewhat successful, the design of these compounds has relied 
on the use aromatic intercalators such as  anthraquinone and other cytotoxic aromatic 
moieties.11  After conjugation to platinum, these compounds show cytotoxicity profiles 
nearly identical to that of the intercalator and therefore provide no clinical benefit over 
the use of the intercalator alone. The synthetic possibilities offered by platinum 
complexes allow the incorporation of not only DNA intercalators, but also different 
fluorophore groups that can be used for imaging studies to gain understanding and 
knowledge of the cellular distribution and action of these drugs. This strategy is a 
relatively non-invasive procedure that has been successfully exploited in the case of 
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several cisplatin-like compounds,12-13 but with very little research devoted to trans-
platinum complexes. By employing the use of both a fluorescent probe and a DNA 
intercalator conjugated to a platinum compound, cellular imaging studies can be 
incorporated to aid in the understanding of drug action. 
In this work we report the anticancer activity and primary insights into the 
mechanism of action of a series of novel water-soluble trans-platinum complexes 
(Figure 5.1) that incorporate an amino ligand composed of an aliphatic carbon chain 
and a planar fluorophore intercalator, NBD (4-Chloro-7-nitrobenzofurazan). 
Interestingly, all three compounds are composed of individual components that are 
inactive when used separately. We also report for the first time the imaging of cellular 
processing of a trans-platin analogue by means of fluorescence microscopy. This is 
especially significant due to the antitumor potency the compounds exhibit when 
compared to cisplatin.  
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Figure 5.1 General Chemical Structure of Trans-NBD Compounds 
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Results and Discussion 
It is well known that platinum compounds, including those with trans geometry, 
target DNA and form bifunctional adducts by covalently binding with guanine and 
adenine nucleobases. The intra- or inter-strand nature of the adducts formed strongly 
depends on the nature of the complex.2,14-16 The rationale for the choice of NBD as 
fluorophore is in addition justified by its ability to intercalate between the nucleobases of 
DNA, a consequence of its high similarity with adenine.17 This fact, therefore, allows all 
compounds the potential capability of a dual mode of action in which the platinum atom 
interacts covalently with the nucleobases while the NBD moiety intercalates with DNA. 
This strategy has been used by several groups,18 but we now include an aliphatic chain 
between the platinum atom and the intercalator that will allow for the modulation of the 
lipophilicity/hydrophilicity of the drug and also make the compound flexible enough to 
allow the NBD molecule to properly intercalate in between the “preferred” nucleobases. 
 
DNA Intercalation of Trans-NBD Compounds 
A key factor in the design of the Trans-NBD series that should drastically 
influence the cytotoxic behavior is the ability of the NBD moiety to intercalate strongly 
with DNA and therefore allow for the formation of uniquely distinct DNA-platinum 
adducts. The un-conjugated NBD moiety has previously been shown to intercalate 
between nucleobases of DNA.17  Therefore it was necessary to understand the 
influence of a platinum center on its ability to bind DNA.  NBD displays a strong 
emission transition in the range between 530 and 550 nm that is quenched by the 
addition of a solution of DNA, indicating that intercalation of the NBD fluorophore with 
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adjacent DNA nucleotides. The results can be cast in the shape of the Scatchard 
equation and the strength of the intercalation can be efficiently quantified and compared 
to that of the known interacalator, ethidium bromide (Table 5.1).  
Ethidium bromide is a cationic dye that is widely used as a probe for native DNA. 
The ethidium ion displays a dramatic increase in fluorescence when it intercalates into 
DNA.19 As seen in Table 5.1, all Trans-NBD complexes show a decrease in 
fluorescence when titrated against DNA, indicating the intercalation of the NBD moiety 
between adjacent DNA nucleobases. The binding strength is similar in all compounds 
and ligands, and is shown to be stronger than that of ethidium bromide. This fact 
reinforces the proposed design of the Trans-NBD series and provides for a secondary 
binding mode in addition to the classical covalent platinum-DNA interaction. The 
covalent-intercalation, “dual” mode of binding, along with the addition of a “flexible” 
carbon chain allows the NBD moiety to intercalate between the preferred nucleobases 
as well as allowing for the modulation of the lipophilicity of the drug. 
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Table 5.1 Binding affinities calculated by fluorometric titration using the Scatchard equation for interaction 
of small molecules with biomolecules. Excitation and emission set at 465 and 535 nm for 2NBD and 
Trans2NBD; 480 nm and 542 nm for 4NBD and Trans4NBD; 485 nm and 550 nm for 6NBD and 
Trans6NBD.  
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Cytotoxicity of Trans-NBD Compounds 
To evaluate the role of both the NBD intercalator and the trans-platinum moiety 
on the cytotoxicity of each compound, IC50 values for all three Trans-NBD compounds 
and linkers (platinum-free primary amine ligand with the NBD moiety) was determined in 
four tumor cell lines. Table 5.2 All complexes are significantly more cytotoxic than the 
NBD-linker alone. In addition, transplatin is known to be inactive in all four cell lines at 
similar concentrations.20 Therefore the increased activity observed is a consequence of 
the combination of both the platinum center and NBD moiety, resulting in a “synergistic” 
effect of combining both inactive components. Trans4-NBD and Trans6-NBD are more 
than twice as potent as cisplatin in the A2780 ovarian cell line and, the less sensitive, 
HCT116 colorectal carcinoma cell line, while both display analogous behavior in PC3 
and MDA cell lines. On the other hand, Trans2-NBD shows a similar or lower profile of 
activity than cisplatin in all four cell lines (Table 5.2). The use of a longer aliphatic chain, 
as in Trans4-NBD and Trans6-NBD should allow for greater flexibility and in turn create 
the potential for both intercalation and covalent platinum-DNA adduct formation. Steric 
effects of the short two carbon chain likely also play a role in limiting the dual mode of 
binding.  Interesting to note, the Trans-NBD compounds show a greater cytotoxicity 
profile than the published cisplatin-NBD, the cis analogue to Trans2-NBD.21  This is 
probably due to the decreased water solubility of the cis derivative, resulting in a drastic 
decrease in cellular accumulation and DNA platination. 
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Table 5.2 Cytotoxic activity of the Trans-NBD complexes and linkers against A2780 (ovarian cancer cell 
line), HCT116 (colorectal carcinoma cell line), PC3 (prostate cancer cell line) and MDA-MB-435 (breast 
adenocarcinoma cell line). 
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Cellular Accumulation and DNA Adduct Formation of Trans-NBD Compounds 
Since the cellular accumulation and frequency of DNA adduct formation correlate 
with the cytotoxic effect of most platinum compounds, the level of cellular uptake and 
DNA platination of the Trans-NBD series was studied after 24 hour treatment with 10 
µM of each drug. All three Trans-NBD complexes accumulate in a similar extent to 
cisplatin in the HCT116 cell line, while only Trans6-NBD has a better influx/efflux ratio 
than cisplatin in the A2780 cell line (Table 5.3). However, none of the Trans-NBD 
complexes reach DNA more effectively than cisplatin (Table 5.3). Assuming that DNA is 
the biological target for the activity of these compounds, it is clear that the different type 
of adducts formed after DNA binding and intercalation result in the formation of lesions 
than are more toxic than traditional bifunctional 1,2-intrastrand DNA crosslinks formed 
by cisplatin. It is highly likely that these more toxic crosslinks are triggering cell signaling 
pathways after platination and different repair mechanisms that are crucial for the 
overall cytotoxicity of the drugs. More interesting is the comparison of cell accumulation 
and DNA binding ability within the series of Trans-NBD compounds.  It is clear that the 
complexes that are able to accumulate within the cell and bind DNA at a higher extent 
(Trans4-NBD and Trans6-NBD) and display a more cytotoxic profile in both, A2780 and 
HCT116 cancer cell lines. In this sense, the lipophilicity of the drug may be playing an 
important role. It is reasonable to assume that Trans4-NBD and Trans6-NBD, while both 
being water soluble, will be more lipophilic than Trans2-NBD as a consequence of the 
longer carbon chain attached to the NBD fluorophore, and thus more capable of 
entering the cells by means of passive transport through the cell membrane.22 
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Table 5.3 Cell accumulation and DNA binding for the Trans-NBD series and cisplatin in A2780 and 
HCT116 cell lines. All values upon treatment with 10 µM drug after 24 hours 
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Cellular Localization of Trans-NBD Compounds 
Finally, knowledge of the processing and distribution of platinum drugs within 
living cells is of paramount importance. Information about whether the drugs are able to 
reach their intended target or if they remain in the cytosol and accumulate in other 
subcellular compartments that are usually associated with drug resistance and export, 
can provide insight into the differential behavior of platinum compounds.  Due to the 
fluorescent nature of the NBD interacalator, fluorescent confocal microscopy can be 
used as a tool to examine and understand drug action and metabolism. As seen in 
Figure 5.2, fluorescent microscopy images of all Trans-NBD compounds in both 
HCT116 and A2780 cells, show high levels of drug localization throughout the cytosol 
and to a lesser extent, inside the nucleus.  This is consistent with the fact that only 
about 10% of the cellular platinum reaches the nucleus of the cells. The decreased 
fluorescence of the Trans-NBD compounds in the nucleus can also be explained due to 
quenching upon intercalation of the NBD moiety on nuclear DNA. Increased 
fluorescence is also observed in the vicinity of the nuclear membrane, likely due to drug 
accumulation within the compartments of the Golgi, responsible for drug efflux and 
endosome recycling.23-24 This pattern of Golgi, endosomal/lysosomal accumulation has 
been noted before with various types of platinum compounds.25 The observed cell 
processing of Trans2-NBD is analogous to that of Trans4-NBD, Trans6-NBD and also 
for the cisplatin analogue Cisplatin-NBD,21 therefore, suggesting that the frequency and 
type of DNA adduct formed play a fundamental role in the overall activity of the Trans-
NBD series. 
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Figure 5.2 Confocal laser scanning micrographs of A2780 and HCT116 cells. After incubation with Trans-
NBD compounds, 10µM for 24hrs at 37
o
C, cells were fixed and observed by confocal laser scanning 
microscopy.  (left panel) Trans-NBD compounds (green) in A2780 cells + DAPI (blue). (right panel) Trans-
NBD compounds (green) in HCT116 cells + DAPI (blue). Cells were grown on 4-well chamber slides 
(Lab-TekII Chamber Slide) for 2-3 days until cells reached near-confluency. Cells were then incubated 
with 10µM of each compound for 24hrs. After treatment, slides were fixed with 3% paraformaldehyde and 
mounted with Vectashield mounting media containing DAPI.  Fluorescence was observed by confocal 
laser scanning microscopy (Zeiss LSM 510). 
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Conclusion 
In conclusion, we have synthesized a new series of trans platinum compounds 
more than twice as potent than cisplatin in the ovarian carcinoma cell line, A2780, and 
colorectal carcinoma cell line, HCT116. The results of cell uptake and DNA binding 
suggest that the higher cytotoxicity observed compared to cisplatin is not a 
consequence of increased cellular accumulation, but of a different and more efficient 
binding mode to DNA, due to an aliphatic amino ligand that incorporates a planar DNA 
intercalator. It is believed that all complexes bind covalently the nucleobases of DNA 
and intercalate between DNA base pairs through the NBD moiety.  Also, the NBD-DNA 
intercalations show a stronger affinity than that observed for ethidium bromide. This 
dual mode of binding likely activates cell signaling pathways and therefore overcomes 
cisplatin-DNA repair mechanisms. When compared within the series of Trans-NBD 
complexes, there is a good correlation between, lipophilicity, cell accumulation, DNA 
binding and cytotoxicity. Fluorescent microscopy shows that the complexes accumulate 
preferentially in the cytosol, with areas of strong fluorescence close to the nuclear 
membrane, where the lysosomes and Golgi apparatus are typically located. This dual 
mode of DNA-binding, covalent and non-covalent, allow for a distinctly different 
cytotoxicity profile that that of cisplatin and could allow for the development of a new 
class of platinum based chemotherapeutics able to overcome current platin drug 
resistance and expand the range of tumors currently treatable with clinical platinum 
drugs.   
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Materials and Methods 
Synthesis of Ligands and Platinum Complexes 
N-(7-nitro-2,1,3-benzoxadiazol-4-yl)ethane-1,2-diamine (2-NBD); N-(7-nitro-2,1,3-
benzoxadiazol-4-yl)buthane-1,4-diamine (4-NBD); N-(7-nitro-2,1,3-benzoxadiazol-
4-yl)hexane-1,6-diamine (6-NBD): BOC–diaminoethane/BOC–diaminobuthane/BOC–
diaminohexane was dissolved in ethanol containing a 10% w/w of Na2CO3, and NBD-Cl 
was added. The mixture was stirred at room temperature overnight, then water was 
added and the product was extracted with diethyl ether. The organic phase was washed 
with brine, dried over Na2SO4 and purified by flash chromatography (CHCl3:EtOAc, 
88:12 / 75:25 / 70:30 for 2-NBD, 4-NBD and 6-NBD respectively). The BOC protecting 
group of the purified intermediate was removed by using trifluoroacetic acid (2 ml) at 
room temperature. After the mixture had been stirred overnight, excess TFA was 
evaporated, and the oily product was treated with diethyl ether to yield the 
trifluoroacetate salt as orange crystals. The compound was neutralized by dissolving it 
in a mixture H2O/Ethanol 1:1 and addition of 1 equivalent of NaOH. The neutral ligand 
was then extracted with CH2Cl2. The organic fractions were dried over K2CO3 and the 
solvent removed under vacuum. The product was dried under vacuum overnight. The 
absence of TFAcetate was confirmed by 19F NMR. 
 
Trans-[PtCl2((N-NBD)ethane-1,2-diamine)(NH3)] (Trans2-NBD): Cisplatin (26 mg, 
0.087 mmol) was suspended in 5 ml of deionized water and one equivalent of AgNO3 
was added. The mixture was stirred at 45ºC for 4.5 hours, then cooled to 5ºC for 2 
hours to allow full precipitation of AgCl. The silver white salt was double filtered through 
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ligand was added (19.34 mg, 0.087 mmol). That solution was stirred at room 
temperature overnight, then filtered. 1.5 ml of HCl 37% were added and the resulting 
solution was stirred at 75ºC for 5 hours. The orange clear solution was concentrated 
under vacuum until a precipitate appeared (~ 3 ml) and then cooled to 5ºC to complete 
the precipitation of the final product. The orange powder was filtered, washed with ice-
cold water, ice-cold ethanol and ether, then dried under vacuum for 24 hours. 1H NMR 
D2O δ (ppm):  8.47(d, 1H); 6.35 (d, 1H); 3.82 (t, 2H); 3.28 (t, 2H). 
195Pt NMR D2O δ 
(ppm):  2148(s) 
 
Trans-[PtCl2((N-NBD)buthane-1,4-diamine)(NH3)] (Trans4-NBD): The same 
procedure as described for Trans2-NBD was followed. 1H NMR D2O δ (ppm):  8.36(d, 
1H); 6.23 (d, 1H); 3.49 (m, 2H); 2.91 (m, 2H); 1.69 (m, 2H).  195Pt NMR D2O δ (ppm):  
2158(s) 
 
Trans-[PtCl2((N-NBD)hexane-1,6-diamine)(NH3)] (Trans6-NBD): The same procedure 
as described for Trans2-NBD was followed. 1H NMR D2O δ (ppm):  8.36(d, 1H); 6.23 (d, 
1H); 3.45 (m, 2H); 2.85 (m, 2H); 1.66 (m, 2H); 1.54 (m, 2H); 1.32 (m, 2H).    195Pt NMR 
D2O δ (ppm):  2164(s). EA calculated for C12 H20 N6 O3 Pt Cl2: C, 25.63; H, 3.59; N, 
14.94. Found: C, 25.63; H, 3.57; N, 14.96. 
 
Cell System 
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HCT116 and A2780 cell lines were cultured in RPMI 1640 (Invitrogen), supplemented 
with 10% calf serum (Atlanta Biologicals) and 1% penicillin/streptomycin (Invitrogen). 
Cells were maintained in logarithmic growth as a monolayer in T75 culture flasks at 
37°C in a humidified atmosphere containing 5% CO2. 
 
Cellular Growth Inhibition 
The MTT assay was used to determine growth inhibition potency of platinum drugs.26  
A2780, HCT116, PC3 and MDA-MB-435 cells were seeded in 96-well plates at 6.5k 
cells/well for A2780, 5k cells/well for HCT116 and MDA-MB-435, and 10k cells/well for 
PC3 and allowed to attach overnight. RPMI 1640 media was removed and 200µL of 
each compound was added after serial dilution to treatment concentrations [50µM – 
0.78µM] in quadruplicate wells and exposed to cells for 72h.  Plates were then washed 
with PBS and 100µL of 5mg/mL MTT solution was added.  MTT solution was incubated 
with cells for 3h at 37ºC. After incubation, MTT solution was removed and 100µL of 
DMSO was added.  Quantification of cell growth in treated and control wells was then 
assessed by measurement of absorbance at 562nm. IC50 values were determined by 
using the standard curve analysis of SigmaPlot. 
 
Cellular Drug Accumulation and Quantification of DNA-Drug Adducts 
A2780 or HCT116 cells were plated in 10cm dishes at 2 million cells/dish and allowed to 
attach overnight. Cells were then treated with 10µM of each drug for 24hrs. After 24hrs, 
drug solution was removed and plates were washed 3x with PBS.  Cells were then 
removed from the dish with trypsin and centrifuged for 5min at 1000xg. Media was 
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removed, cell pellet was washed three times with PBS, cells were counted and 
resuspended in 250μL of ddH20.  Samples were digested following published 
methods.27  For DNA analysis experiments, DNA was extracted using a DNeasy blood 
and tissue kit (Qiagen) according to the manufacturer‟s protocol. Extent of DNA 
platination and cellular platinum accumulation was measured on a Varian ICP-MS. 
 
Fluorescence Spectrophotometric Titration 
Excitation and emission wavelengths were set to 465 and 535 nm for the ligand 2-NBD 
and complex Trans2-NBD; to 480 nm and 542 nm for the ligand 4-NBD and the 
complex Trans4-NBD and 485 nm and 550 nm for the ligand 6-NBD and the complex 
Trans6-NBD. Bandwidths were set to 5 nm and 20 nm for the excitation and the 
emission, respectively. All fluorescence spectra were measured in a Cary 
Spectrophotometer instrument with an arc xenon lamp. The absorption of the sample at 
the wavelength of excitation was less than 0.1 in order to obviate inner filter effects. The 
fluorimetric titration was carried out at room temperature. Fixed amounts (10 µl) of a 
12.5 mM solution of CT DNA were added to a 0.4 µM solution of the metal complex, 
both in Tris/HCl buffer (5mM Tris/HCl and 50 mM NaClO4, pH = 7.39) and emission 
spectra were monitored until saturation was reached. Binding data were cast into the 
form of a Scatchard plot of r/Cf vs. r using the equation r/Cf = K(n-r) for ligand-
macromolecule interactions with non-cooperative binding sites28-30, where r is the 
number of moles of Ru complex bound to 1 mol of CT DNA (Cb/CDNA), n is the number 
of equivalent binding sites, and K is the affinity of the complex for those sites. α was 
calculated according to α = (Ff-F)/(Ff-Fb), where Ff and Fb are the fluorescence of the 
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free and fully bound drug at the selected wavelength, and F is the fluorescence at any 
given point during the titration.31 Kb is obtained from the slope of the plot. 
 
Confocal Laser Scanning Microscopy 
A2780 and HCT116 cells were grown on 8-well chamber slides (Lab-TekII Chamber 
Slide) for 2-3 days until cells reached near-confluency. The cells were treated with 
Trans2-NBD, Trans4-NBD, and Trans6-NBD (10µM) for 24hrs. After treatment, slides 
were washed 3x with ice-cold PBS and fixed with 3% paraformaldehyde.  
Paraformaldehyde was removed and cells were washed again with 3x PBS and allowed 
to dry.  Slides were then mounted with Vectashield mounting media containing DAPI.  
Fluorescence was observed by confocal laser scanning microscopy (Zeiss LSM 510).  
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Chapter 6: Conclusion 
 
While platinum chemotherapy represents one of the most utilized forms of cancer 
treatment, all current therapies have innate problems due to inherent tumor resistance 
and a limited availability of susceptible tumor types. The inherent resistance of these 
tumors and the toxic side effects associated with platinum chemotherapy are, in part, a 
result of metabolic deactivation.  By understanding the balance between cytotoxic 
activity and metabolic deactivation it may be possible to defer many of the toxic side 
effects associated with chemotherapeutics, and thus provide for substantial increases in 
mean tolerated dosages and increase the number of tumors treatable by platinum 
drugs. Two possible ways to diminish these types of metabolic interactions have been 
described in this thesis and are (1) through the use of carboxylates ligands to “fine-tune” 
the reactivity of trans-platinum compounds and thus balance the cytotoxic and 
pharmacokinetic profiles and (2) through the introduction of a non-covalent antitumor 
agent, TriplatinNC, which not only presents a new mode of DNA binding, distinct from 
any clinical platinum agent, but also allows for the elimination of covalent Pt-protein 
adduct formation.   
While the cis platinum geometry has yielded three clinical platinum based drugs, 
the second factor in the success of any platinum chemotherapeutic is the range of 
treatable tumor types over that of the current clinical regime.  By extending the platinum 
geometry to include trans based platinum derivatives, this work has also attempted to 
create platinum compounds which are able to treat tumor types other than that of 
cisplatin and other cis based compounds. By developing a series of Trans-NBD 
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compounds which include a transplatinum DNA binding agent and a DNA interacalator, 
we have created transplatinum based drugs which show significant improvements in 
cytotoxic activity over than of cisplatin. The goal is to combine both improvements in 
metabolic deactivation and novel antitumor profiles thus creating a class of compounds 
which can outperform the current clinical antitumor platinum drugs and ultimately 
provide for a promising outlook for the future of cancer chemotherapeutic treatments. 
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Abstract 
TriplatinNC is a highly positively charged, (+8) noncovalent derivative of the 
phase II clinical platinum drug, BBR3464.  TriplatinNC exhibits a distinct mode of high 
affinity DNA interaction, increased levels of cellular accumulation, and a significant 
cytotoxic profile in mastocytoma, ovarian carcinoma, and cisplatin-resistant ovarian 
carcinoma cell lines. Here, it is shown, through use of fluorescent-tagging and confocal 
colocalization experiments that TriplatinNC rapidly localizes to the nucleolar 
compartment in HCT116 and A2780 cells. Due to its cationic nature, it was considered 
that TriplatinNC likely interacts with nucleic acid components of the nucleolus, that is, 
ribosomal DNA, and its transcripts. 32P-metabolic labeling of HCT116 cells determined 
that the production rate of 47S rRNA precursor transcripts is drastically reduced as an 
early event after drug treatment. Subsequently, there is a marked increase in p53 
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protein at 12hrs, followed by a robust and continuous G1 arrest at 24 and 48hrs.  
Morphological characteristics of the apoptotic process are apparent within 24hrs, 
including: reduction in cell size, membrane blebbing, and cytosolic vacuolization. 
TriplatinNC induces cleavage of mitochondrial-dependent and -independ-ent initiators of 
apoptosis, procaspase-9 and -8, followed by activation of the effector procaspase-3, 
and downstream target, Parp-1. Furthermore, utilizing the isogenic HCT116 p53+/+ and 
p53-/- cell lines, it was determined that these processes, are not dependent upon the 
presence of p53 protein. 
 
Introduction 
The increased proliferative rate of cancer cells relies on a concomitant 
upregulation of ribosomal biogenesis in order to meet the cellular demands for protein 
synthesis 1-4. The biogenesis of ribosomes is a coordinated process that largely takes 
place in the nucleolar compartment of the cell.  The nucleolus is formed around tandem 
arrays of more than 400 copies of ribosomal RNA (rRNA) genes as they are 
transcribed, processed, and assembled into ribosomal subunits 5. Recently, rRNA 
synthesis has emerged as a shared target of many anticancer agents 6. The platinum-
based drugs, oxaliplatin, and to a lesser extent, cisplatin, inhibit the transcriptional rate 
of the 47S rRNA precursor transcript, while the antimetabolite, 5-fluorouracil (5-FU), 
disrupts processing of the precursor into mature 28S, 18S, and 5.8S rRNA transcripts. 
In each case, the effects are surprisingly early events; observed within hours after cell 
treatment. This implies that inhibition of rRNA processes may be an early determinant of 
the antiproliferative activity of these drugs. Of course, the effects of oxaliplatin, cisplatin, 
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and 5-FU are not limited to rRNA processes. They are nonselective, genotoxic drugs 
that modify, or incorporate into the total pool of nucleic acid 7-9. Limiting genotoxic 
events by drug-targeting only nucleic acid within the nucleolus and specifically, rRNA 
synthesis, is an interesting challenge for small molecule therapeutics.  
Unlike the nucleus and other membrane-bound organelles, there is no evidence 
of a membrane or membrane-like structure separating the nucleolus from the 
surrounding nucleoplasm. In theory, any soluble molecule could diffuse in and out of the 
nucleolar compartment.  Because of sequence similarities in nuclear and nucleolar 
localization signals, it is currently accepted that targeting of a specific molecule to the 
nucleolus results from its direct or indirect interaction with components of the nucleolus, 
that is, ribosomal DNA and its transcripts 10. Positive charge is a major factor in 
localization and retention of proteins to the nucleolus. Mutagenesis studies of nucleolar 
proteins, such as nucleolin, fibrillarin, and the viral HIV TAT, determined that clusters of 
the positively charged amino acids arginine, and lysine serve as nucleolar localization 
signals 11-12. Furthermore, poly-arginines and -lysines, containing more than six amino 
acids, rapidly penetrate cellular membranes and localize specifically to the nucleolar 
region of cells 13-15. 
TriplatinNC is a highly positively charged, (+8) non-covalent derivative of the 
phase II clinical platinum drug, BBR3464 16 (Fig. A.1 A,B). The crystal and molecular 
structure of TriplatinNC associated with a double-stranded B-DNA dodecamer 5′-
d(CGCGAATTCGCG)2  at 1.2 Å resolution (PDB:2DYW), shows formation of phosphate 
clamps, involving two modes of DNA binding: "backbone-tracking", by following along 
the phosphate backbone of one strand, or "groove-spanning", by crossing over the 
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minor groove to interact with both strands 17. The phosphate clamp motif is a discrete 
third mode of DNA binding, distinct from intercalation or minor groove binding. These 
interactions are mediated through hydrogen bonding, and are analogous to the "arginine 
fork”, an important motif for protein-DNA interactions, where positively charged 
guanidino groups of arginine, interact with negatively charged oxygens of DNA 
phosphate 18-20, (Fig. A.1C). We have extended this analogy with the hypothesis that the 
charged nature of TriplatinNC, like poly-arginines, may facilitate its localization to the 
nucleolar compartment within cells.  
       In this report, we reveal remarkable differences in the cellular localization 
pattern of TriplatinNC compared to cisplatin. The fluorophore-drug conjugate, 
TriplatinNC-NBD, but not cisplatin-NBD, rapidly accumulates within the nucleolar region 
of the cell. As an early event upon cellular treatment with TriplatinNC, there is a 
resulting decrease in the production rate of 47S rRNA precursor transcripts. Further 
studies detailed in this report set a timeline of the subsequent morphological, 
antiproliferative, and apoptotic events. 
  
153 
 
 
 
 
Figure A.1 Structures of (A) BBR3464 and (B) TriplatinNC. The noncovalent polynuclear compound, 
TriplatinNC, is a direct structural analog of the Phase II drug BBR3464, where the labile chloride ion is 
replaced by the amine group, NH2(CH2)6NH2. (C) Chemical similarity of "arginine-fork" (left), and  
"phosphate-clamp" (right) interactions, http://pubs.rsc.org/en/Content/ArticlePDF/2010/CC/C0CC01254H  
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Results and Discussion 
TriplatinNC rapidly accumulates within the nucleolus. To determine differences in 
the cellular localization pattern of TriplatinNC compared to Cisplatin, each compound 
was labeled with the small fluorophore, 7-nitrobenzoxadiazole (NBD). The resulting 
drug-NBD conjugates, Cisplatin-NBD and TriplatinNC-NBD (Fig. A.2A), retain charge 
properties and inhibitory concentration (IC) values comparable to that of the parent 
compounds (Fig. A.3). Confocal microscopy showed that TriplatinNC-NBD, but not 
Cisplatin-NBD, rapidly accumulates to punctate regions of the nucleus in HCT116 colon 
carcinoma and A2780 ovarian carcinoma cell lines (Figure A.2 B,C). In colocalization 
studies, the distinct nuclear localization patterns of TriplatinNC overlaps the signal of the 
commonly used nucleolar marker, Fibrillarin, a ribonucleoprotein methyltransferase 
involved in the first steps of ribosomal RNA (rRNA) processing (Figure A.2D). Due to 
this unique pattern of localization, and the charged nature of the drug, it was considered 
that TriplatinNC was likely to interact with ribosomal DNA/RNA within the nucleolus. 
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Figure A.2 Fluorescently-tagged TriplatinNC localizes to the nucleolus. (A.) Structures; Fluorophore 
conjugates Cisplatin-NBD and TriplatinNC-NBD. (B.) Confocal Microscopy; The cellular distribution of 
NBD-Cisplatin (green) in A2780 cells after 24hrs incubation in 10µM drug. (C.) NBD-TriplatinNC (green) 
in A2780 and HCT116 cells after 2hrs incubation with 20µM drug, respectively. The DNA is subsequently 
stained with DAPI (blue) as reference. (D.) Colocalization (orange) of NBD-TriplatinNC (green) with the 
nucleolar marker, fibrillarin (red), in HCT116 cells after 4hrs incubation in 20µM drug. Anti-fibrillarin signal 
was detected using a secondary antibody conjugated to Alexa-fluor 647. 
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Figure A.3 MTT Assay; A2780 or HCT116 cells were treated with the indicated concentration of drug for 
72hrs. In each graph the drug-NBD derivative is denoted in dark gray and the parent compound in light 
gray. (A.) A2780 cells treated with TriplatinNC-NBD and TriplatinNC. (B.) HCT116 cells treated with 
TriplatinNC-NBD and TriplatinNC-NBD. (C.) A2780 cells treated with Cisplatin-NBD and Cisplatin. (D.) 
HCT116 cells treated with Cisplatin-NBD and Cisplatin. Percent Inhibition is calculated as: 1-(N/N0), 
where N=treated samples and N0= untreated control samples. Data are shown as mean ± s.d. 
representative of at least 2 independent experiments. 
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As an early event, TriplatinNC disrupts the rate of rRNA transcription. Initiation of 
rDNA transcription requires assembly of a specific multiprotein complex that binds to the 
rDNA promoter containing RNA Polymerase I (Pol I), and two Pol I specific transcription 
factors, upstream binding protein (UBF), and the promoter selectivity factor complex, 
SL1 21. The binding specificity of Pol I at rDNA promoters is conferred by SL1 22, 
comprised of the transcription factor TBP (TATA-Box Binding Protein) and several 
auxiliary TBP-associated factors 23-24. The ability of TriplatinNC to inhibit the interactions 
of TBP with DNA was examined in vitro using the Electromobility Shift Assay (EMSA). 
TriplatinNC was found to reduce TBP-DNA complex by 50% using between 0.63 and 
1.25µM drug concentrations (Fig. A.4A), which is nearly 100-fold more effective than the 
similar, less positively charged (+6) platinum agent, AH44 (Fig. A.5). This study 
suggests the possibility that TriplatinNC may inhibit RNA transcription by displacing 
DNA-binding proteins required for this process. 
   To determine whether TriplatinNC affects the rate of rRNA transcription in vivo, 
HCT116 cells were treated with varying drug concentrations for 5.5hrs, and then 
metabolically labeled according to the scheme depicted in Fig. A.4B. The 47S rRNA 
precursor transcript is sequentially cleaved to yield the mature 28S, 18S, and 5.8S 
rRNAs. As cells are pulsed with 32P-radiolabeled orthophosphate for 30 min. followed by 
a 3h chase, the abundance of newly formed 47S precursors, 32S intermediate cleavage 
products, and mature 28S and 18S rRNAs are sufficiently labeled for visualization by 
autoradiography (6). It was evident that treatment of cells with TriplatinNC inhibits the 
production rate of 47S rRNA precursor transcripts in a dose dependent manner (Figure 
A.4B). It does not appear that TriplatinNC affects the rate of 47S rRNA processing, as 
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the abundance of 32S, 28S, and 18S rRNAs decrease proportionally to that of the 
precursor. 
    The transcriptional activity of rRNA genes has been shown to change in 
accordance with the cell cycle 25. rRNA transcription levels are highest in S and G2 
phases, nonexistent in mitosis, and rebounding in G1 
26-27. Therefore, it was important to 
consider whether the inhibitory effect of TriplatinNC on the rate of rRNA transcription 
was direct, or if rRNA transcription levels were merely downregulated as an indirect 
effect of changes within the cell cycle. The latter would be likely if there were an 
increase in the population of cells in G1 (when rRNA levels are lower). For this purpose, 
HCT116 cells treated with TriplatinNC were subjected to cell cycle analysis by flow 
cytometry (Figure A.6 A, B). In cells treated with 20µM TriplatinNC ([IC90]) for 6hrs, there 
were modest changes that occurred within the cell cycle. The population of cells in G1 
decreases slightly from 37% to 30% compared to untreated control cells, while the 
population of cells within S+G2 increases slightly from 63% to 70%. These results imply 
the disruption of rRNA transcription is an early event of cellular treatment with 
TriplatinNC, and does not result from changes in the cell cycle.  
  
159 
 
 
Figure A.4 TriplatinNC competitively inhibits TBP-DNA interaction and interferes with rRNA transcription. 
(A.) EMSA; Lanes 3-9; 2nM 
32
P-labeled DNA incubated with 0.08, 0.16, 0.31, 0.63,1.25, 2.5, and 5uM 
drug, respectively, followed by 100ng rTBP protein. Lane 2 is the ‘TBP/DNA complex’ positive control. 
Lane 1 is the ‘free DNA’ control containing DNA only. (B.)
 32
P-Pulse/Chase Metabolic Labeling; Samples 
were treated with or without drug according to the experimental outline. Lanes 1-8 were treated with 0.78, 
1.6, 3.1, 6.3, 12.5, 25, 50, 100µM drug, or without drug in lanes 1 and 2. 1.5µgs total RNA was analyzed 
for each sample. Ethidium Bromide (EtBr) staining of 28S rRNA was used as a loading control. 
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Figure A.5 A. Structures of TriplatinNC
+8
 and AH44
+6
. B. EMSA; Lanes 3-9; 2nM 
32
P-labedled AdML DNA 
oligo incubated with  0.032, 0.16, 0.8, 4, 20, 100, and 500uM drug, respectively,  followed by 100ng rTBP 
protein. Lane 2 is the ‘TBP-DNA complex’ positive control. Lane 1 is the ‘free DNA’ control, containing 
DNA only. 
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Figure A.6 TriplatinNC induces G1 cell cycle arrest. (A.) Flow Cytometry; Cell cycle analysis of HCT116 
cells treated for 6, 24, and 48hrs with 20µM TriplatinNC (IC90) after RNase B treatment and staining with 
propidium idodide.  (B.) Modfit software analysis of histograms (excluding sub-G1). Data points are shown 
as mean ± s.d. of 2 independent experiments with 2 replicates per sample (C.) Western Blot Analysis; 
Time course analysis of p53, p21, and p27 protein expression after 20µM TriplatinNC for 3, 6, 12, and 
24hrs. B-Actin is used as a loading control. 
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At 24hrs, TriplatinNC induces a G1 cell cycle arrest.  Anticancer therapeutics cause 
proliferative arrest generally through induction of a classical signaling pathway 28. 
Central to this pathway is the stabilization of p53 protein by serine/threonine kinases, 
followed by transactivation of the cyclin-dependent kinase (CDK) inhibitor, p21. 
Increased protein levels of p21 inhibit CDK activities resulting in cell cycle arrest. This 
pathway is induced by cisplatin, which has been shown to arrest cells at the G2-
checkpoint as an attempt to repair DNA damage before cells enter mitosis 29-30. In 
agreement with these studies, HCT116 cells treated with 20µM cisplatin ([IC90], Fig. 
S1D) were shown to induce S-phase accumulation at 24hrs, and finally G2 arrest at 
48hrs (Fig. A.7). Treatment of HCT116 cells with 20µM TriplatinNC, on the other hand, 
induced an earlier arrest in G1 at 24hrs continuing to 48hrs. The increase in the number 
of cells in G1 was mostly at the expense of the proportion of cells undergoing DNA 
replication in S-phase, which decreased 52% at 24hrs and 77% at 48hrs compared to 
the control. (Fig. A.6 A,B). As expected, there is a substantial stabilization of p53 protein 
levels leading into the G1 arrest at 12 and 24 hrs after treatment with TriplatinNC (Fig. 
A.6 C). However, p21 expression levels are not concomitantly upregulated in the 
classical manner. Surprisingly, p21 protein expression levels decreased at 6 and 12 hrs, 
and increase only to basal level at 24hrs. Furthermore, the protein expression levels of 
p27, a similar CDK inhibitor with the potential to cause cell cycle arrest 31, also 
decreased. These data suggest that the G1-arrest induced by TriplatinNC may not 
depend on classical signaling events. The fact that TriplatinNC induces G1-arrest in the 
HCT116 isogenic cell lines lacking either p53 or p21 (Fig. A.8), furthers this point. It is 
tempting to speculate that TriplatinNC may disrupt the cell cycle at G1, because S-
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phase has the highest requirements for rRNA production 32. The consideration that G1-
cyclin proteins may be synthesized in insufficient amounts to allow for the transition into 
S-phase is a subject of continuing research.  
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Figure A.7 Flow Cytometry; Cell cycle analysis of HCT116 cells treated for 0, 24, and 48hrs with 20uM 
Cisplatin after RNase B treatment and staining with propidium idodide.  
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Figure A.8 Flow Cytometry; Cell cycle analysis of HCT116, HCT116 p53-/-, and HCT116 p21-/- cells 
treated for 0, 24, and 48hrs with 20uM TriplatinNC after RNase B treatment and staining with propidium 
idodide.  
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TriplatinNC causes rapid proliferative arrest and cell death independently of p53 
status. In cells undergoing apoptosis, activated cysteine proteases, caspases-3, -6, -7,   
result in cleavage of cytoskeletal proteins and fragmentation of nuclear DNA. These 
events result in visible changes to the morphology of the cell including cell shrinkage, 
chromatin condensation, cytosolic vacuolization, and membrane blebbing 33. Changes 
in physiology of HCT116 cells treated with 20µM TriplatinNC-NBD were visualized using 
confocal microscopy after 2, 10, and 30hrs of treatment (Fig. A.9A). After 10hrs of 
treatment, cells are much smaller in size and exhibit prolific cytosolic vacuolization. After 
30hrs of treatment, blebbing and disintegration of the outer membrane is apparent. 
      Nearly all cancers harbor genetic defects that directly, or indirectly, inhibit 
normal proapoptotic, or tumor suppressor functions of p53 28. For this reason, we asked 
whether the absence of p53 affects the ability of TriplatinNC to effectively induce 
proliferative arrest and cell death. HCT116 p53+/+ and p53-/- cells were treated with 
20µM cisplatin or TriplatinNC for 12, 24, 48, or 72hrs. Using the MTT assay, it was 
determined that the ability of cisplatin to inhibit cell growth was significantly limited in the 
absence of p53 (Fig. A.9B). However, the inhibitory effects of TriplatinNC on cell growth 
was unaffected by the absence of p53 protein (Fig. A.9C). In support of these results, 
we asked further whether the absence of p53 affects the ability of TriplatinNC to inhibit 
colony-formation, or reproductive viability, using the clonogenic survival assay. HCT116 
p53+/+ and HCT116 p53-/- cells were treated with 20µM TriplatinNC for 24, 48, and 
72hrs (Fig. A.9C, Fig. A.10). The percentage of cells that failed to replicate was 
determined to be between 63-75% after 24hr, 86-90% after 48hrs, and 85-99% after 
72hrs. There was no significant difference in cells with or without p53. 
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Figure A.9 TriplatinNC causes rapid proliferative arrest and cell death. (A.) Confocal Microscopy; 
Morphological effects on HCT116 cells treated with 20µM TriplatinNC for 2, 10, and 30hrs include a 
reduction in cell size, membrane blebbing, and cytosolic  vacuolization (white arrows). (B.) MTT Assay; 
Comparison of growth inhibition in HCT116 p53+/+ (lt gray) and p53-/- (dk gray) cells treated with 20uM 
cisplatin or TriplatinNC. Percent Inhibition is calculated as: 1-(N/N0), where N=treated samples and N0= 
untreated control samples. Data points are shown as mean ± s.d. of 2 independent experiments with 3 
replicates per sample. **p<0.05, ***p<0.005 (C.) Clonogenic Survival Assay; Comparison of reproductive 
viability in HCT116 p53+/+ cells and p53-/- cells treated with 20uM TriplatinNC for 24 and 48hrs. Plates 
are representative of 4 independent experiments with 2 replicates per sample; mean ± s.d. of the 
combined data is shown in Fig. S5. 
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Figure A.10 Clonogenic Survival Assay; Comparison of colonies formed in HCT116 p53+/+ cells (black) 
and HCT116 p53-/- cells (gray) treated with 20uM TriplatinNC. Percent Inhibition is calculated as: 1-
(N/N0), where N=treated samples and N0= untreated control samples. Data are shown as mean ± s.d. 
representative of 4 independent experiments. 
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After 48hrs, TriplatinNC induces a robust apoptotic signaling cascade. TriplatinNC 
induces apoptosis in mast cells through activation of the mitochondrial-dependent 
pathway initiator, procaspase-9, and the downstream effector, procaspase-3 34. In 
extension of these studies, it was determined whether TriplatinNC induced 
accumulation of the activated forms of procaspase-9 and procaspase-3 in p53(+/+) as 
compared to p53(-/-) HCT116 isogenic colon carcinoma cell lines. Both cells lines show 
a time-dependent increase in active caspase-9 and caspase-3 after treatment with 
20µM TriplatinNC (Fig. A.11A). At 30 or 55hrs after treatment in p53-/- cells, there is 
less accumulation of active caspase-9 compared to the untreated control than in p53+/+ 
cells. However, the abundance of active caspase-3 appears to be unaffected by the 
absence of p53. Therefore, it was asked whether caspase-3 may be activated also by 
the initiator of the mitochondrial-independent pathway of apoptosis, caspase-8. 
    Caspase-8, has the ability to activate procaspase-3 through both 
mitochondrial-dependent and -independent apoptotic pathways. In the mitochondria-
dependent pathway, caspase-8 cleaves BID to tBID, which translocates to the 
mitochondria and causes damage by culminating an efflux of death promoting proteins 
such as cytochrome-C. These events, in turn, lead to activation of procaspase-9, 
followed by procaspase-3. In the mitochondrial-independent pathway, caspase-8 
instead directly activates procaspase-3, and downstream substrates such as Parp-1, 
eventually leading to cell death 35. In HCT116 cells treated with 20µM cisplatin for 
48hrs, it was determined that the abundance of active caspase-8 (p18) and downstream 
target, Parp-1, is severely reduced in cells lacking p53 as compared to the wild-type 
control (Fig A.11B). However, treatment with 20µM TriplatinNC for 48hrs induced similar 
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levels of active caspase-8 and Parp-1 in p53+/+ and p53-/- cells (Fig. A.11C).  
Furthermore, TriplatinNC does not induce the cleavage of BID into tBID (Fig. A.12), 
therefore, the mitochondrial-dependent and independent pathways are likely activated 
independent of each other 36. 
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Figure A.11 TriplatinNC induces activation of caspases independent of p53. (A.) Western Blot Analysis; 
Timecourse analysis of cleaved caspase-9 and -3 protein in HCT116 p53+/+ and p53-/- cells treated with 
20µM TriplatinNC for 5, 15, 30, and 55hrs. (B., C.) Comparison of cleaved caspase-8 and Parp-1 protein 
in HCT116 p53+/+ and p53-/- cells treated with 20µM Cisplatin or TriplatinNC at 48hrs. B-Actin was used 
as a loading control. 
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Figure A.12 Western Blot; Comparison of BID (p22) and the active form, tBID (p15) proteins in HCT116 
p53 treated with 20uM Cisplatin or TriplatinNC at 48hrs. B-Actin was used as a loading control.  
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Summary. This study highlights remarkable features and cellular consequences of the 
noncovalent polynuclear platinum agent, TriplatinNC. Within hours, TriplatinNC 
accumulates within cells and localizes specifically to the nucleolus. The immediate 
decrease in rate of rRNA transcription, followed by G1 arrest, is a likely result of unique 
'phosphate clamp' DNA binding motif employed by TriplatinNC, which competitively 
inhibits TBP-DNA interactions. TriplatinNC activates the apoptotic program through 
mitochondrial-dependent and -independent caspase pathways. TriplatinNC induces 
morphological changes in cells consistent with the process apoptosis, including 
shrinkage in cell size, cytosolic vacuolization, and membrane blebbing. Furthermore, 
TriplatinNC effectively induces proliferative arrest and cell death independent of p53. 
The activity of TriplatinNC in human cancer cell lines extends to antitumor activity 
observed in vivo using the 2008 human tumor xenograft mouse model. (Fig. A.13 and 
Table A.1). The results presented here support a basis for selective targeting of rRNA 
processes as a strategy for p53-independent induction of apoptosis in cancer cells and 
pave the way for an entirely new class of platinum-based anticancer therapeutics. 
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Figure A.13 2008 ovarian tumor human xenograft model: Animals were treated on days 0, 4, 8 with either 
25mg/kg TriplatinNC by ip injection, saline (0.1ml/10g body weight), or on days 0, 7, 14 with 4mg/kg 
cisplatin by ip injection. 
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Table A.1 Effect of cisplatin and TriplatinNC against the 2008 ovarian tumor xenograft mouse model. 
Drug efficacy was assessed by measuring the TGI (tumor growth inhibition) on day 10, indicating % 
decrease in tumor volume in drug treated animals vs. control, GDI (tumor growth delay index) indicating 
the number of days the tumor takes to reach 3 (a) or 4 (b) times its starting size, and AGD (absolute 
growth delay), calculated as median time in days to reach 3 times starting tumor volume. 
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Materials and Methods 
Drug Synthesis. Cisplatin was synthesized as previously described; [Wong, E.S.Y.; 
Giandomenico, C.M., Patent No. 09678595]. TriplatinNC and AH44 were synthesized 
as described previously (16). The synthesis of TriplatinNC-NBD and Cisplatin-NBD are 
described in the Supplemental Methods section. 
Cell Culture and Drug Treatments. HCT116, HCT116 p53-/-, and A2780 cell lines 
were cultured in RPMI 1640 (Invitrogen), supplemented with 10% calf serum (Atlanta 
Biologicals) and 1% penicillin/streptomycin (Invitrogen). Cells were maintained in 
logarithmic growth as a monolayer in T75 culture flasks at 37°C in a humidified 
atmosphere containing 5% CO2. For drug treatment studies, unless otherwise noted, 
the molar drug:cell ratio was kept constant by seeding 5x104 cells/mL media throughout.  
Confocal Fluorescence Microscopy. 5x104 cells were seeded on chamber slides 
(Lab-Tek II) in media. 24hrs after seeding, cells were treated with TripaltinNC-NBD or 
Cisplatin-NBD at the indicated times and concentrations. After removing the media, 
cells are washed with PBS and mounted as described below. For Immunofluorescence 
of fibrillarin, cells were permeabilized with 0.5% Triton-X in PBS for 10 min. and blocked 
in PBS/Casein for 1hr at room temperature. 1:200 dilution of primary antibody, anti-
fibrillarin (cell signaling, clone C13C3) was added overnight at 4°C, then a 1:500 dilution 
of secondary antibody anti-rabbit IgG Alexa 647 conjugate (cell signaling) for 3 hrs at 
room temperature. The antibodies are then fixed with 3% paraformaldehyde for 15 min. 
at room temperature. All slides were mounted in VectaShield with DAPI (Vector Labs) 
and viewed using a Zeiss LSM 510 confocal microscope. 
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Flow Cytometry. HCT116 cells were drug treated for 6, 24, and 48hr. 1x106 cells were 
suspended in 1ml of propidium  iodide solution (3.8mM sodium citrate; 0.05mg/ml  
propidium iodide; 0.1% Triton X-100) with added RNAse B (7000units/ml) and kept in 
the dark at 4°C. Cells were analyzed by flow cytometry on a CoulterElite XL-MCL 
(Beckman Coulter). Twenty thousand events were acquired and analyzed using Modfit 
software. 
Metabolic Labeling and rRNA analysis. 2x105  HCT116 cells were grown in 6-well 
plates in 4ml RPMI/10% FBS media for 24hr. Cells were drug treated for 5h. For 
phosphate depletion, complete media was replaced with phosphate-free DMEM/10% 
dialyzed FBS containing drug and incubated for 30 min. before the addition of 15µCi/ml 
32P-orthophosphate (Perkin Elmer) and further 30 min. incubation. Medium was again 
changed to RPMI/10% FBS drug-containing medium for 3hr and total RNA was isolated 
using RNeasy  (Qiagen). RNA concentration was determined using a Nanodrop. 1.5ug 
of total RNA was separated on a 1% agarose-formaldehyde gel. After electrophoresis, 
28S rRNA quantities were visualized with Ethidium Bromide as a loading control. Gels 
were placed on Whatman paper and dried for 2hr at 80°C under vacuum suction. Dried 
agarose gels were exposed to x-ray film. 
Electromobility Shift Assay. 2nM end-labeled dsDNA (24mer 5’-
GAAGGGGGGCTCTAAAAGGGGGTG-3’ containing the AdML TATA box.) was 
incubated for 15 min. at 30°C with or without drug in a final volume of 10µs reaction 
buffer (20mM Hepes-KOH, pH7.9, 25mMKCl, 10% glycerol, 0.025% NP-40, 100 µg/mL 
BSA, 0.5mM DTT, 0.1mM EDTA, and 2mM MGCl2). Where indicated, 100ng rTBP 
(Santa Cruz) was added to the reactions and was further incubated for 30 min. The 
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reactions were separated by electrophoresis in a 6% native polyacrylamide gel in 0.5x 
TBE buffer (45mM Tris-HCl, 44mM boric acid, and 2mM MgCl2). The gel was dried and 
exposed to x-ray film. 
Growth Inhibition Assay. Cells were seeded in a 96-well plate at 5 x103 cells/well in 
100µl media and allowed 24hrs to attach.  Cells were then drug treated for a period of 
72hrs. After removal of drug, the cells were treated with 0.5mg/mL MTT reagent [(3,4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma] in media for 3hrs at 37°C.  
The MTT reagent was removed and 100µl of DMSO was added to each well. The plate 
was then incubated on a shaker at room temperature in the dark. The 
spectrophotometric reading was taken at 570nm using a microplate reader.  
Clonogenic Survival Assay: 2x104 HCT116 +/+ and HCT116-/- cells were seeded in 
3ml of medium in a 6-well plate. After 24hrs of incubation, cells were drug treated for a 
24hr period. 250 or 2500 cells were seeded into 10cm dishes and allowed to grow for 
10-14 days to form colonies. These were then fixed by methanol and stained by 0.1% 
crystal violet. Colonies consisting of more than 50 cells were counted. Plating efficiency 
and surviving fraction were determined for each drug. 
Immunoblot Analysis: Primary antibodies used were p53 (cell signaling, # 9282), p21 
(Santa Cruz, clone F-5), p27 (cell signaling, clone SX53G8.5), total caspase-3 (cell-
signaling, 9662), total caspase-8 (cell signaling, clone IC12), cleaved caspase-9 (cell 
signaling, #9501), cleaved Parp (cell signaling, # 9541), and B-Actin (Abcam, ab8226). 
After drug treatments, both floating and adherent cells were harvested. Cells were 
washed with ice-cold PBS, repelleted, and, resuspended in SDS lysis buffer (62.5mM 
179 
 
Tris-HCl, pH 7.5, 5% glycerol, 4% SDS, 4% complete protease inhibitor (Roche), 5% 
BME). After homogenization, proteins were resolved on 7.5-15% polyacrylamide gels, 
transferred to PVDF membrane, and blocked in 5% non-fat milk at room temperature for 
1 hr. The membranes were probed with primary antibodies overnight, followed by 
secondary anti-rabbit, or anti-mouse antibodies conjugated to horseradish peroxidase 
(Cell Signaling, Thermo Scientific). Chemiluminescent protein bands were visualized on 
X-ray film. 
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Abstract 
The interactions of polynuclear platinum complexes with human serum albumin 
were studied. The compounds examined were the ―non-covalent‖ analogs of the 
trinuclear BBR3464 as well as the dinuclear spermidine-bridged compounds differing in 
only the presence or absence of a central -NH2-
+ (BBR3571 and analogs). Thus, 
closely-related compounds could be compared. Evidence for pre-association, 
presumably through electrostatic and hydrogen-bonding, was obtained from 
fluorescence and circular dichroism spectroscopy and Electrospray Ionization Mass 
Spectrometry (ESI-MS). In the case of those compounds containing Pt-Cl bonds, further 
reaction took place presumably through displacement by sulfur nucleophiles. The 
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implications for protein pre-association and plasma stability of polynuclear platinum 
compounds are discussed. 
 
Introduction 
Polynuclear platinum complexes (PPCs) containing two or three platinum units 
linked by alkanediamine or polyamine chains comprise a structurally distinct class of 
anticancer active platinum compounds, Figure B.1.1 A distinct feature of these 
compounds is the presence of a central moiety capable of pre-association or ―non-
covalent‖ (hydrogen-bonding and electrostatic) interactions with biomolecular targets. 
The three global pharmacological factors controlling platinum drug cytotoxicity and 
antitumor activity are cellular uptake, the frequency and structure of DNA adducts, and 
the extent of metabolizing interactions. The presence of the central unit (platinum-
tetraam(m)ine coordination sphere or the polyamine nitrogen) in polynuclear platinum 
compounds allows for modulation of these pharmacological factors and may affect drug 
efficacy. 
The role of pre-association in dictating the final products of reaction of PPCs with 
biomolecules has been assisted greatly in the trinuclear case by the synthesis and 
evaluation of ―non-covalent‖ analogs where the Pt-Cl bonds are displaced by a 
substitution-inert NH3 or a ―dangling‖ amine H2N(CH2)6NH3
+ (structures Ia or Ib, Figure 
B.1).2-3 Similar strategies can be used for polyamine-bridged dinuclear compounds. 
Further, the synthetic strategies involved in producing linear polyamine-bridged species 
automatically give rise to a precursor where the central nitrogen is blocked, usually by a 
carbamate such as t-butyl (Boc).4 This pair of compounds then only differs in charge 
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and the presence or absence of a central protonated nitrogen atom. The central 
nitrogen atom is susceptible to selective attack using, for example, various carbamate 
or amide blocking groups (structures II, IIa, and IIb, Figure B.1).5 
The rate of DNA platination as well as the amount of long-range interstrand 
crosslinks (where the sites of platination are separated by up to 4 intervening base 
pairs) is affected by charge and hydrogen-bonding capacity of the linker.6 For 1,4 
interstrand crosslink directional isomers (3′ → 3′ and 5′ → 5′ crosslinks) are formed. The 
relative proportion of these adducts is dependent on hydrogen-bonding and charge 
effects within the linker.7-8 The X-ray crystal structure of a duplex DNA co-crystallized 
with Ib demonstrated a new mode of DNA ligand binding—a phosphate clamp—where 
hydrogen-bonding interactions with the phosphate backbone may be arranged in a 
modular manner.9 
Intracellular platinum accumulation and cytotoxicity are also affected by charge. 
In this case, a perhaps counter-intuitive observation is that cell uptake actually 
increases with charge.3,10-11 Interestingly, cellular uptake of the spermidine-bridged 
dinuclear compound II is greater than that of the blocked derivative IIa.11 In these cases 
enhanced cytotoxicity is always correlated with greater cellular uptake.11-12 In 
mechanistic studies with phospholipids, a ―non-covalent‖ interaction of Ia was also 
observed, suggesting one possible mechanism for membrane transport of these highly 
charged species.13 
In this contribution we examine the reactions of polynuclear platinum compounds 
with human serum albumin (HSA) and show for the first time the presence of a pre-
associated or ―non-covalent‖ interaction of a platinum drug on the protein. Reactions in 
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plasma, and especially with HSA, are generally considered responsible for the 
metabolic deactivation of platinum-based drugs. Understanding the molecular details of 
such interactions may allow for strategies to manipulate their extent with consequent 
effects on cellular uptake and even therapeutic index. 
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Figure B.1 Structures of pairs of trinuclear (BBR3464 I, Ia, Ib) and dinuclear (BBR3571 II, IIa, IIb) studied 
for pre-association effects on human serum albumin (HSA).  
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Results and Discussion 
The effects of charge on polynuclear platinum complex binding to human serum 
albumin (HSA) were examined with two sets of compounds. Firstly, the trinuclear 
BBR3464 I was compared with its non-covalent analog Ia and secondly, the effect of 
blocking groups in the central nitrogen of the spermidine-linked dinuclear species was 
evaluated (II, IIa, IIb). See Figure B.1 for structures. Global changes in protein 
conformation can be assessed by circular dichroism (CD) and fluorescence 
spectroscopy.14-15 The CD spectrum of HSA exhibits two negative bands in the 
ultraviolet region at 208 and 220 nm characteristic of an α-helical structure of the 
protein. The fluorescence from excitation of HSA at 298 nm reflects changes in the 
microenvironment of the tryptophan 214 residue, serving as a tool to obtain information 
about conformational changes of the protein.14 A decrease in fluorescence of the lone 
tryptophan of HSA is interpreted as a conformational change making the amino acid 
more accessible to water quenching. 
 
Trinuclear platinum complexes 
Fluorescence spectroscopy 
At t = 0 the relative decrease in fluorescence is concentration dependent for both 
BBR3464 and the ―non-covalent‖ analog Ia. Over time the relative decrease for 
BBR3464 is significantly greater than at t = 0 for all concentrations whereas for the 
―non-covalent‖ analog there is little or no further perturbation of the system, Figure B.2. 
 
 
191 
 
 
 
 
 
Figure B.2 Changes in fluorescence of HSA treated with trinuclear platinum compounds. Note no 
significant change for the “non-covalent’ analog over time. 
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CD Spectroscopy 
The CD spectrum of HSA incubated with PPCs is time and concentration-dependent. 
Immediately upon mixing 1:1 ratios of Pt complex:HSA the ellipticity of the negative 
band at 208 nm is increased (to more negative values) and the spectra do not change 
over a 24 h time period, Figure B.3. At t = 0 the spectra for BBR3464 (3) and Ia (4) are 
superimposable. In contrast when 10:1 ratios are used, the spectrum corresponding to 
the BBR3464 reaction (1) changes and the ellipticity is reduced (less negative values). 
In fact the spectra become similar to those observed for 20-fold excesses of either c-
DDP or its trans isomer upon extensive incubation with HSA and diminution of the α-
helical content of the protein.15 Likewise, the binding of the ruthenium antitumor 
drug trans-[RuCl4(Im)2]
- (Im = imidazole) induces considerable concentration-dependent 
change (up to 15%) of the secondary structure upon binding.16 These results and others 
17-18 are therefore consistent for the concept of bond-formation at the higher 
concentration. The most likely binding sites in all cases remain the sulfur amino acids 
and the CD results in general are consistent structural transitions of HSA being 
dependent on the state of the cysteine Cys34.19 In contrast to all these cited cases 
where bond formation is expected to occur, there is little or no change for the ―non-
covalent‖ analog (5) at the higher ratio, Figure B.3. Thus, the pre-association is also 
indicated to actually increase the order of the secondary structure with an enhancement 
of α-helical content. 
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Figure B.3 CD spectra of HSA incubated with compounds I or Ia at different ratios; drug:HSA, 1:1 and 
10:1 after 24 h. Note no significant change for the “non-covalent” analog after 24 h. (*) Spectra of I (3) 
and Ia (4) overlap from 195-250 nm. 
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ESI-Mass spectrometry 
It is reasonable to conclude from both the fluorescence and CD data that the spectral 
changes induced by Ia, which are invariant over time, represent a ―pre-association‖ or 
non-covalent binding to the protein. At t = 0 the binding of BBR3464 also represents a 
significant contribution from the non-covalent ―pre-association‖ and that further changes 
are due to bond formation. To confirm the presence of this interaction, the compound Ia 
was incubated with rHSA and the mixture examined by ESI-mass spectrometry, Figure 
B.4. It is observed in the mass spectrum that a noncovalent interaction between the 
polynuclear platinum compound Ia and rHSA takes place after a very short incubation 
period. There is a 1015 Da shift in the deconvoluted spectrum (Figure B.4B) obtained 
after incubation reveals that rHSA which corresponds to a 1:1 complex Ia with rHSA 
with the presence of one of NO3
- counter ion from the complex. Mass spectrometry has 
also been used to directly observe c-DDP binding 20 and also Cys34 binding to gold of 
gold-based antiarthritic drugs.21 In the present case initial studies with BBR3464 caused 
precipitation and no clean spectra were obtained—further studies are in progress. 
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Figure B.4 (A) Nano-ESI-MS of rHSA incubated with Ia. rHSA-ligand bound peaks are designated with 
(*). (B) Deconvoluted mass spectrum showing a mass shift of 1015 Da, corresponding to the addition of 
Ia + one NO3
-
.  
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Dinuclear spermidine-linked compounds 
Designed synthesis of polyamine backbones gives a series of exceptionally 
potent compounds which mimic successfully the biological activity of BBR3464.4,12,22  
The critical feature in the biological activity is linked to the presence of a central charged 
-NH2-
+ on the polyamine linker. The role of pre-association in dinuclear polyamine-
linked compounds can be examined by comparing the reactions of the charged species 
and its uncharged or blocked analog. Interestingly, the relative decrease in fluorescence 
at 1:1 ratios was significantly less for the blocked derivatives. In this case, however the 
presence of Pt-Cl bonds does mean that over time platinum-protein bond formation may 
take place and this is reflected in an enhanced fluorescence decrease over time for all 
compounds, Figure B.5. It is of interest to note however, that this decrease is not as 
great as that seen for BBR3464. In agreement with the changes in fluorescence the CD 
spectrum of HSA bound to BBR3571 after 48 h appears similar to that of BBR3464 at 
high Pt:HSA (10:1) ratios (data not shown). 
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Figure B.5 Changes in fluorescence of HSA treated with dinuclear platinum compounds. 
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It is generally considered that chemical changes of platinum compounds on HSA 
lead to deactivation.14,23  A study of a series of mononuclear and dinuclear derivatives 
of meso-1,2-bis(4-fluorophenyl)ethylenediamine showed strong binding to HSA by 
hydrophobic and electrostatic interactions, leading to reduced cellular uptake and 
decreased potency.24 A pharmacological principle is that free (non-protein-bound) drug 
is active, being able to diffuse readily to tissue. Therefore to evaluate and quantitate the 
binding of PPCs to HSA, BBR3464 and Ia were incubated and the ultrafilterable protein 
unbound fraction was quantified for selected time points, Figure B.6. Analysis by ICP-
OES shows a decrease in Pt content immediately upon mixing, t = 0, for both BBR3464 
and Ia. This initial decrease in Pt content represents the non-covalent, ―pre-association‖ 
of the Pt complex with protein. The Pt content corresponding to BBR3464 decreases 
with time, representing a displacement of the Pt-Cl bond and a formation of the 
covalently bound Pt-protein species (where covalent is used to indicate Pt-amino acid 
residue formation independent of strict contributions of covalent or coordinate bonding). 
In contrast, ICP-OES analysis of Ia shows a constant Pt concentration from t = 0 
through t = 24 h. Due to the presence of the substitution-inert -NH3 group, the initial pre-
association is not followed by a covalent Pt-protein interaction. Similar behavior was 
observed for Ib. 
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Figure B.6 ICP-OES analysis of Pt content in ultrafiltrate of BBR3464 and Ia after incubation with HSA for 
selected time points. 
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Conclusions 
The results show that the initial reaction of human serum albumin with trinuclear 
platinum compounds is one of ―pre-association‖, similar to that observed for DNA and 
phospholipids. The mass spectral confirmation is the first, to our knowledge shown for 
platinum antitumor agents. The strength of binding is apparently stronger than that seen 
for free spermine, spermidine or the cation [Co(NH3)]6
3+, where the CD changes upon 
incubation were minimal compared to free HSA.25 The ―pre-association‖ observed for I 
and Ia can be also observed for complexes II—where the presence of a blocking group 
diminished the initial interaction as a cause of diminished charge and hydrogen-bonding 
capacity of the central nitrogen. The proposed binding sites for platinum on HSA are the 
Cys-34 and Met-298, located on the exterior of the protein in sub-domains I and II.14-
15,20,23 
There are a number of interesting points to consider based on this 
understanding. Human serum albumin is a versatile transport protein and receptor for a 
variety of ligands and drugs. The primary function of HSA is the transport of fatty acids 
but since it carries a negative 17 charge, it is also responsible for shuttling a wide 
variety of metal ions, steroids, and a variety of pharmaceuticals. The crystal structure of 
human serum albumin has allowed the identification of the principal ligand-binding 
domains located in the hydrophobic cavities of sub-domains IIA and IIIA.26-27  In 
principle the receptor sites for the highly-charged cations as represented by PPCs in 
this study should be distinct from the Cys and Met covalently-binding sites. It may, 
therefore, eventually be possible to plot the migration of the pre-associated form to the 
platinated species. Secondly, the identified metabolic products of BBR3464 can be 
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mimicked by reactions with small sulfur nucleophiles such as glutathione and 
methionine.28-30 HSA constitutes roughly 60% of the mass of plasma proteins with a 
concentration of ∼40 mg mL-1. It is highly likely therefore that HSA binding could 
contribute to these metabolic deactivation reactions, as suggested also for some similar 
dinuclear complexes.24 Finally, as a corollary, the results for Ia and Ib suggest that 
these non-covalent compounds may ―by-pass‖ the deactivation associated with Pt-S 
bond formation. This is especially important for Ib. This 8+ compound is taken up into 
cells in a significantly greater concentration than either BBR3464 or Ia, and as a result 
has demonstrated in vitro cytotoxicity equivalent to cisplatin. The ―non-covalent‖ 
compounds have shown a new mode of DNA binding distinct from intercalation and 
minor-groove binding. The interaction, but not deactivation, on HSA suggests a new and 
promising profile for a polynuclear platinum drug. 
 
Experimental 
Sample preparation 
All platinum compounds were as prepared previously.2-5 Human serum albumin 
(essentially fatty acid free) was purchased from Aldrich/Sigma. Recombinant human 
serum albumin (rHSA) (Recombumin®), expressed in Saccharomyces cerevisiae, was 
a generous gift from Delta Biotechnology Limited (Nottingham, UK). A stock solution of 
phosphate buffered saline ([phosphate] = 150 mM, pH 7.35 at 37 °C, [NaCl] = 120 mM, 
[KCl] = 2.7 mM)) (PBS) was prepared and used for all reaction solutions in order to 
mimic physiological conditions. HSA was incubated with platinum reactions at a 
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constant temperature of 37.5 °C prior to obtaining spectroscopic data, which was 
acquired at room temperature. 
 
UV-Visible spectroscopy (UV-Vis) 
Absorption spectra were recorded on a JASCO V-550 UV-Vis spectrophotometer. HSA 
concentration was determined from the absorption spectrum, taking the absorbance of a 
1 mg mL-1 solution at 280 nm (λmax Trp-214) as 0.55.
15 
 
Circular dichroism (CD) 
CD spectra were measured on a Jasco J-600 UV dichrometer using a 0.3 mm (open-
ended side plate) quartz crystal cuvette. A bulk solution of HSA was prepared at a 38.5 
mg mL-1 (1.12 × 10-4 M) concentration. HSA/Pt reactions were conducted at a 1:1 and 
10:1 (drug:HSA) stoichiometry. Spectral measurements were recorded at t = 0 and 
selected time intervals. 
 
Fluorescence spectroscopy 
Fluorescence measurements were conducted on a Cary Eclipse Fluorimeter with the 
excitation and emission wavelengths set at 279 and 310 nm, respectively, with a scan 
rate 120 of nm min-1. PMT voltage was set manually to 409 V. The reactions of platinum 
compounds were studied at various reactant ratios, predominantly 1:1 and 10:1 
(Pt:HSA). An initial concentration for a 10:1 reaction was prepared for each drug. Each 
solution was then diluted to the specific concentration needed for the desired ratio. Each 
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reactant was incubated in a shaker bath at 37.5 °C for 45 min prior to reacting. Separate 
measurements were taken at t = 0 and appropriate time intervals. 
 
Electrospray Ionisation Mass Spectrometry (ESI-MS) 
Experiments were conducted on a Waters/Micromass (Manchester, UK) QTOF-2 mass 
spectrometer. A custom built nano-ESI source was used with a capillary voltage of 2.1 
kV and a cone voltage of 36 V. Source block temperature was maintained at 150 °C. 
ESI-solutions consisted of methanol:water (50:50 v/v) with 0.1% formic acid. The 
solutions were infused at 0.5 μL min-1 using a Harvard Apparatus Model 22 syringe 
pump (Harvard Apparatus, Holliston, MA). Data acquisition and processing were carried 
out using the MassLynx 4.0 software. Stock solution of AH 44 was 500 μM in water and 
made fresh before ESI-MS experiments. Aliquots from the stock solution of rHSA, 139 
μM, were mixed with the polynuclear platinum compound Ia in a 1:2 molar ratio in water 
and incubated at 37 °C, for 15 min. Incubated samples were mixed in the ESI solution to 
give a final rHSA concentration of approximately 40 μM. 
 
Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES) 
1.8 mM solutions of each complex were prepared in phosphate buffer and added to 0.6 
mM HSA such that the final concentration of complex was 0.9 mM; (3:1; drug:HSA) The 
mixture was reacted at 37 °C and 100 μL aliquots were removed at t= 0, 0.5, 2, 6, and 
24 h. Aliquots were then centrifuged through a Microcon YM-10 10 000 kDa membrane 
filter at 14 000 g for 30 min to isolate ultrafiltrate. The centrifuge cup was upturned in a 
second eppendorf and then centrifuged at 1000 g for 3 min to isolate the protein-bound 
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fraction. Samples were digested following published methods. Pt content was recorded 
at 214 nm and 265 nm, at each time point, using a Varian ICP-OES. Data are reported 
as percentage of Pt in control vs. Pt per time point. 
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